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Colorectal cancer (CRC) prevention using screening colonoscopy relies upon the
identification and removal of precancerous polyps or adenomas. Recently, an increase in CRC
cases has been observed in individuals who have undergone screening colonoscopy before their
next prescribed screening or surveillance interval, underscoring inherent limitations of routine
colonoscopy as a complete preventive measure. Increasing evidence suggests that these “interval
cancers” are most likely the product of missed or overlooked precancerous lesions. Specifically,
interval cancers have a predilection for the proximal colon and their molecular features are
associated with serrated polyps, lesions that due to their endoscopic morphology are difficult to
detect and completely resect. To determine risk factors for precancerous lesions, especially those
hard to detect endoscopically, we have performed a retrospective analysis of a
gastroenterologist’s endoscopy practice in central Connecticut. Using statistical models, we
associate demographic and lifestyle factors with polyp occurrence, pathology and colonic
location. Interestingly, we demonstrate a potent interaction between smoking history and daily
aspirin use that predicts polyp incidence and multiplicity. This finding has important clinical
implications, as aspirin is a putative chemoprevention agent for CRC, yet this protective effect
may be limited to certain sub-populations of patients.

David Alden Drew – University of Connecticut, 2014

Aberrant crypt foci (ACF) are macroscopic epithelial abnormalities that occur within the
human colon and may represent the earliest precancerous lesion detectable by high-definition
chromoendoscopy. ACF exhibit pathologic and molecular abnormalities similar to those
observed in advanced neoplasia. Therefore, they may serve as an important surrogate marker for
CRC risk, but recently their reliability has been questioned and they have rarely been studied in
the proximal colon. We describe a comprehensive clinical trial designed to characterize human
ACF molecularly and pathologically, in context of colonic location. Novel techniques,
combining microdissection with nanoproteomic and high-throughput mass spectrometry-based
genotyping platforms, were established as effective methods to detect mutations and measure
downstream signaling consequences within biopsy specimens. Proximal ACF are demonstrated
to be frequently dysplastic, possess oncogenic mutations and associate with synchronous
neoplasia and ACF multiplicity. As such, they may serve as a surrogate marker of the at-risk
colonic mucosa and, importantly, may represent a subset of the missed lesions that contribute to
interval cancers. With careful consideration of these studies, clinicians may identify individuals
who may benefit from shorter surveillance intervals or advanced endoscopic approaches, such as
high-definition chromoendoscopy.
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CHAPTER 1

INTRODUCTION

1.1 OVERVIEW OF COLORECTAL CANCER
1.1.1 Colorectal cancer epidemiology
Colorectal cancer (CRC), or cancer of the large intestine, is currently the third most
common cancer in the United States. In 2014, it is estimated 136,830 individuals will be
diagnosed with CRC resulting in approximately 50,000 deaths. Age is strongly associated with
CRC incidence, with more than a third of all CRC deaths occurring in the population aged 80
years or older. The death rates are higher in black populations and lowest in Asian individuals.
Men have a slightly higher lifetime probability of receiving a CRC diagnosis (5.0%) compared to
women (4.7%)[1].

In Connecticut, CRC incidence is approximately equivalent to the national average (50.2
and 50.9 cases per 100,000, respectively, in non-Hispanic, white males), but has the second
lowest CRC mortality rates in the nation (16.2). The incidence trends compared to the national
rates are similar for non-Hispanic white women. Nationally, incidence rates have been declining
over the past two decades; and at a slightly higher rate over the last 10 years compared to the
1990s. This is largely believed to be due to improved access to screening methods and
widespread-use of detailed surveillance guidelines. Still the public health concern remains as
1

CRC ranks third among all cancer deaths with only an approximate 65% five-year survival rate,
necessitating further advances in cancer screening and early detection[1].

1.1.2. Colorectal carcinogenesis – pathways to cancer.
The majority of CRC cases are sporadic in origin, not inherited, despite the fact that
family history of CRC is an established risk factor the disease. Vogelstein and Fearon provided a
paradigm for sporadic CRC tumorigenesis in 1990 [2]. This ‘traditional’, or ‘classical’, pathway
describes the step-wise accumulation of spontaneous or induced genetic alterations over the
course of 10-15 years. Among cancer researchers, this adenoma-carcinoma sequence is also
commonly called the ‘Vogelgram’ in reverence to its founding father. Mutational activation of
oncogenes or inactivation of tumor suppressors leads to the formation of low-grade dysplastic
tumors, or ‘adenomas’, that subsequently develop into high-grade dysplastic tumors, or
‘carcinoma-in-situ’ (CIS), and ultimately undergo malignant transformation. The majority (6575%) of CRC is believed to develop via this pathway[3]. A detailed discussion of adenoma
pathology and their endsoscopic morphology are provided in the next section.

Over the last two decades, an ‘alternative’ pathway for CRC tumorigenesis has been
established. Under this model, CRC develops from pathologically distinct precancerous polyps
and separate molecular mechanisms from those described by Vogelstein. Early oncogenic
mutations or epigenetic aberrations lead to the formation of hyperplastic (non-dysplastic) lesions
prior to malignant transformation. Many of these lesions’ crypts display a ‘serrated’, or sawtooth-like appearance, leading to the pathway being commonly called the ‘serrated’ pathway.
This pathway may be responsible for up to 30% of CRC by the most liberal estimates; more
2

conservative estimates suggest the incidence is closer to a still significant, 20%[4]. A discussion
of serrated polyps, their endoscopic morphology, and their distinct molecular mechanisms from
traditional adenomas are provided in the following sections.

The minority (~5%) of CRC is the result of inherited germ-line mutations to key CRCassociated genes. The two most commonly inherited CRC disorders are familial adenomatous
polyposis (FAP) and hereditary non-polyposis colorectal cancer (HNPCC), or Lynch syndrome.
FAP is caused by inherited mutations to the Adenomatous polyposis coli (APC) gene, HNPCC is
due to mutations in mismatch repair (MMR) genes including hMLH1, hMSH2, hMSH3, hMSH6,
hPMS1, and hPMS2 [5]. These cancers are still believed to follow the pathologic progressions
laid out by the two distinct pathways. FAP CRCs distinctly follow the adenoma-carcinoma
sequence, while Lynch syndrome lesions may follow either pathway depending on the early
genetic mutations that occur.

1.1.3 Polypoid and nonpolypoid lesions of the colorectum.
Colorectal lesions fall under two broad categories that align with their pathways to CRC:
traditional adenomas and serrated polyps (Figure 1).

Traditional adenomas, or simply

‘adenomas’, are prevalent in a quarter of the population by age 50 and approximately half by age
70[6]. Traditional adenoma’s main pathologic criteria are cellular hyperproliferation with the
presence of cytologic dysplasia. Microscopically, crowded, hypercellular colonic crypts with
elongated, enlarged, and pencil-shaped nuclei characterize this low-grade dysplasia (Figure 2).
Nuclei are also pseudostratified with hyperchromasia. The presence of other features such as
complex crypt architecture, loss of cellular polarity and nuclear pleomorphism signify high-grade
3

Figure 1. Pathways to CRC. Two distinct pathways of CRC are defined by their precancerous
lesions. Left; the traditional adenoma-carcinoma sequence as proposed by Vogelstein et al. and is
believed to be responsible for approximately three-quarters of CRC cases. Right; the alternative
serrated pathway to CRC as proposed by Jass et al. responsible for up to the remaining quarter of
CRC cases. Less than five percent of CRCs are the result of an inherited CRC genetic disorder,
but these CRCs will still follow one of the two pathways depending on their genetic alterations.
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Figure 2. Representative photomicrographs (H&Es) of polyps and adenomas depicting
characteristic cellular architectures.

A-C) Hyperplastic polyp (A, x100), showing simple tubular crypts oriented towards the
muscularis mucosa (A) and a symmetrical proliferative zone at the base of the crypts with
serration of the lining cells (B, x200; C x400, arrowheads).
D, E) Sessile serrated adenoma (D, x100), high power reveals a predominance of micro-vesicular
cytologic features within the cells lining the crypts (E, x200, white arrowheads) and have
complex crypt structure oriented towards the muscularis mucosa (D, black arrowheads) with an
asymmetrical proliferative zone extending to the side-wall (E, black arrowheads).
F) Combined (mixed) dysplastic-sessile serrated adenoma (x100). Note a serrated lesion on the
left side of the field without dysplasia (black arrowhead), combined with low-grade dysplasia
tubular adenoma on the right side of the field (white arrowhead). Such lesions suggest possible
progression of serrated lesions to dysplasia and carcinoma.
G, H) Tubular adenoma with low-grade dysplasia. Note smooth non-serrated lumen of the
crypts and orientation in various directions. Details of cytologic dysplasia are evident (H, x200),
characterized by elongated, cigar-shaped hyperchromatic nuclei with high N/C ratio.
K) Presence of the serrated pattern in a tubular adenoma (x100).
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dysplasia or a CIS. Traditional adenomas are classified into three distinct pathologic sub-types:
tubular adenomas (TA), tubulovillous adenomas (TVA), and villous adenomas (VA) (Figure 1,
left). TAs have a distinct tubular-shaped crypt architecture that is more or less irregular or
branched. VAs’ crypts have villi- or finger-like projections of dysplastic epithelium with a thin
fibro-vascular core. TVAs show both tubular and villous crypt architectures. A summary of the
World Health Organization’s (WHO) pathologic criteria for each of these lesions can be found in
the appendix[7]. Endoscopically, tubular adenomas tend to be smaller, pedunculated polyps
while villous adenomas tend to be larger and sessile (flat or non-polypoid)[8]. Cancers arising
from these lesions are more prevalent in the distal colorectum (from splenic flexure to rectum,
including the descending and sigmoid colon) [9].

Serrated polyps (SPs) have recently been recognized as a premalignant or neoplastic
lesion. Originally thought to be benign due to their lack of dysplasia, they are now considered a
precancerous lesion due to the presence of distinct CRC molecular signatures within these
polyps. A discussion of the divergent molecular pathways between adenomas and SPs follows in
the next section. With few examples of a clear histologic link between SPs and CRC, it remains
unclear exactly when or how dysplasia develops in these lesions and how quickly they undergo
malignant transformation. The pathologic guidelines for SP classification have been undergoing
constant refinement for the past decade. Therefore, their prevalence in the population has been
difficult to accurately quantify[10]. However, it is believed they account for approximately 25%
of the polyps in the population[11]. SPs are currently classified by the WHO into three histologic
categories: hyperplastic polyp (HP), sessile serrated adenoma/polyp with or without cytological
dysplasia (SSA), or traditional serrated adenoma (TSA). Serrated refers to the microscopic
8

appearance of the crypt upon transverse section, where cellular hyperproliferation, or
hyperplasia, leads to the appearance of a serrated or saw-tooth lumenal surface. Upon crosssection these crypts have a stellate or star-like luminal appearance[7]. Detailed pathologic
descriptions of SPs can be found in the appendix.

HPs and SSAs both have elongated proliferative zones and the presence of serration. HPs
are the most common of the SPs (~80% of all SPs) and typically have a lower degree of serration
and a straight, non-distorted crypt architecture from the luminal surface to the muscularis mucosa
(Figure 2 A-C). HPs are sometimes further classified into microvesicular hyperplastic polyps
(MVHP), characterized by small droplet mucin within the epithelial cytoplasm with few goblet
cells, and goblet cell hyperplastic polyps (GCHP), characterized by an overabundance of goblet
cells and absence of cytoplasmic mucin. Endoscopically, HPs are typically flat or sessile, small
(<5mm), more frequent in the distal colon and are mostly considered to be benign[11].

SSAs (~20% of all SPs) typically have a higher degree of serration extending throughout
the crypt compared to HPs (Figure 2 D&E). They are specifically characterized by the presence
of disorganized crypt architecture, resulting in crypts becoming dilated or branched, particularly
in the base of the crypts (Figure 2 D&E, black arrowheads). Endoscopically, these lesions are
sessile or flat, as their name implies, larger than 5 mm in size and are typically located in the
proximal colon (from cecum through the transverse colon up to the splenic flexure, including the
ascending colon and the hepatic flexure)[11]. Additionally, these lesions are commonly
associated with the presence of a mucous coating or ‘mucous cap’[12].

9

SSAs traditionally are non-dysplastic, but occasionally SSAs will have foci of traditional
adenoma-like dysplasia (Figure 2F). These polyps were previously termed ‘mixed polyps’, but
for the sake of clarity, should not convey that crypts of the polyp have both serrated and
dysplastic features within the same crypt. Instead, within the polyp there are areas that resemble
SSA histologically and immediately adjacent areas, with an abrupt transition, that resemble
traditional adenomas. When crypts show both tubulovillous features and serrated lumenal
surfaces within a polyp, the polyp is considered a TSA (Figure 2 G&H). These lesions are very
rare, accounting for less than 2% of all SPs. Endoscopically, TSAs can be sessile or
pedunculated, are usually larger than 5 mm in size and are distally located. They are, however,
considered to be precancerous lesions [11].

1.1.4 Molecular mechanisms of carcinogenesis.
The adenoma-carcinoma sequence as originally described by Vogelstein provides a stepwise accumulation of genomic aberrations leading to the formation of malignant carcinomas.
The process begins with an early inactivation mutation of the APC gene causing a truncation of
the APC protein within a colonic epithelial cell. This is typically caused by a point or frameshift
mutation in the “mutation cluster region”, or the gene region between nucleotides 1263-1589
which encompasses the β-catenin binding motif [13]. The APC protein is an important negative
regulator of β-catenin, an important downstream molecule of the canonical Wnt signaling
pathway. β-catenin performs dual roles within a cell, supporting cell adhesion as well as
transcriptional activation of the TCF/LEF family of transcription factors that are responsible for
numerous cell processes including cell proliferation and differentiation. Under normal
conditions, the cytoplasmic pool of β-catenin is stabilized through the action of the APC-Axin10

glycogen synthase-3β (GSK3β) complex, which phosphorylates β-catenin targeting it for
ubiquitination and subsequent degradation. When the APC protein is truncated as a result of
mutation, the APC-Axin-GSK3β destruction complex cannot be formed leading to cytoplasmic
accumulation of β-catenin and its subsequent nuclear translocation driving aberrant transcription.
These mutant cells can undergo monoclonal expansion causing focal dysplasia within the colonic
epithelium [3].

Cellular proliferation is further accelerated through the constitutive activation the
mitogen-activated protein kinase(MAPK) signaling cascade. The RAS/RAF/MAPK signaling
pathway mediates cellular proliferation in response to extracellular growth factor receptor (e.g.
EGFR, FLT3, ERBB2) signals. Oncogenic mutations to the RAS family – KRAS, HRAS, and
NRAS – commonly occur within many different human cancers. Mutations to the RAS family of
genes result in constitutive activation of downstream proteins (including MEK1/2 and ERK1/2)
and aberrant cellular proliferation[14]. KRAS mutations (point mutations within codons 12 and
13) are commonly associated with traditional adenomas considered an early initiating event in
the Vogelgram as they are found in ~40% of CRC[3].

As adenomas form from dysplastic foci, additional genomic and genetic aberrations will
begin to accumulate as a result of the uncontrolled proliferation. As a result, many adenomas
may develop a chromosome instability (CIN) phenotype leading to additional loss of gene
function via mutation or chromosomal loss. It has been acknowledged that the order of early
stage mutations are less important in terms of progression, but instead the quantity of molecular
aberrations. The TP53 gene is an important tumor suppressor gene implicated in the Vogelgram
11

and definitively believed to be one of the last events, just prior to the adenoma-carcinoma
transition. p53 is activated in response to cell stressors causing cells to respond to damage by
upregulating DNA repair pathways or inducing senescence or apoptosis. Mutations to p53 are
detected in up to 70% of CRC[3].

The serrated pathway, while believed to be a step-wise progression like the adenomacarcinoma sequence, has a distinct subset of associated molecular abnormalities specific to
serrated carcinoma development[15]. The requirements for SP initiation and progression include
MAPK pathway activation and aberrant genomic promoter methylation, termed CpG island
methylator phenotype (CIMP).

MAPK constitutive activation occurs primarily through

mutations to BRAF (V600E mutation), but can also be the result of KRAS (codons 12 and 13)
mutation. BRAF mutations primarily occur in MVHPs and SSAs, while KRAS mutations are
primarily found in TSAs[4].

CIMP is determined by a panel of CpG islands, or regions of cytosine-guanine
dinucleotide repeats, within CRC-associated tumor suppressor gene promoters that when
hypermethylated lead to gene silencing[16,17]. Important CRC associated tumor suppressors,
including p16 (CDKN2a), an important negative regulator of cyclin-dependent cell-cycle, and
MLH1 (as previously discussed with HNPCC) harbor CpG islands within their promoters and
their loss may lead to serrated tumor progression. There are multiple degrees of CIMP depending
on how many panel promoters exhibit hypermethylation, resulting in CIMP-high (CIMP-H) or
CIMP-low (CIMP-L) classifications. Traditional adenomas tend to be CIMP negative (CIMP-).
The exact mechanism by which CIMP is acquired still needs to be determined, but upregulation
12

of DNA methyl-transferases (DNMTs) in response to increased proliferation or intake of dietary
methyl donors (i.e. folate/folic acid) are putative explanations[4,16,17].

Microsatellite instability (MSI), is another feature commonly observed in serrated
colorectal lesions, but infrequently described in traditional adenomas (microsatellite stable or
MSS). MSI is determined by measuring the length of multiple mono-nucleotide repeats, or
microsatellites, as a marker of genomic stability[18,19]. Patients with defects to MMR genes, not
unlike those with Lynch syndrome, show high microsatellite instability. It is possible for this
genomic instability to be acquired somatically, perhaps through methylation and subsequent loss
of MLH1. MSI, like CIMP, has multiple classifications representative of the level of genomic
instability, MSI-high (H) and MSI-low (MSI-L)[20]. Because MSI may be an acquired
phenotype due to epigenetic silencing of MMR genes, it has been classified as an associated, but
not required genetic abnormality for SP initiation [4].

As such serrated carcinomas are broadly classified into two categories: BRAF mutant,
CIMP-H, and either MSS or MSI-H -or- KRAS mutant, CIMP-L, and MSS. The first class of
carcinoma is strongly linked with the serrated pathway, making SSAs their likely precursor
lesion. The second classification is presumed to arise from TSAs, which share these molecular
characteristics. BRAF mutant, CIMP-H, MSI-H serrated carcinomas tend to be proximally
located and may contribute significantly to interval colon cancers as discussed in the next
section.[15,17,21,22]
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1.2 PREVENTION OF COLORECTAL CANCER
In 1950, CRC was the most common cause of cancer death. Today it is the third leading
cause of cancer deaths, in part because of changes in lifestyle, the introduction and widespread
awareness of preventive measures, and advances in adjuvant therapies [1].

1.2.1. Colorectal cancer screening
Identification of precancerous lesions and routine polypectomy during endoscopy is
credited with a subsequent lowering of CRC incidence[23,24]. However, despite increases in
screening colonoscopy rates[25,26], CRC remains a leading cause of cancer deaths in the U.S.
Standard preventive screening by total colonoscopy with bowel preparation is recommended for
individuals who are aged 50+ years or have a history of CRC[27]. The traditional model of colon
cancer pathogenesis provides a paradigm to explain the success of colonoscopy as a prevention
tool. Because CRC develops slowly over decades, early neoplastic changes can be readily
identified within the colon years before malignant transformation occurs[2]. Depending on the
type of polyp removed during screening endoscopy, different surveillance intervals have been
recommended by the American Gastroenterological Association (Table 1)[28].

Fecal occult blood tests are another widely used type of CRC screening. This method
tests the stool for the presence of blood as a non-specific marker for CRC or advanced polyps or
adenomas, but has been shown to significantly reduce CRC mortality in asymptomatic
individuals[27,29].
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Table 1. Surveillance interval guidelines based upon lesion pathology, size and multiplicity.
Lesions identified during baseline colonoscopy
Recommended Surveillance Interval*
(most advanced finding)
(in years, *assuming average risk)
No polyps
10
Small (<1 cm) HP in distal 20-cm of colon
10
1-2 small (<1 cm) TA
5-10
3-10 TA, regardless of size
<3
1+ TA, ≥ 1 cm
3
1+ VA, regardless of size
3
High-grade dysplasia or CIS
3
1+ Small SSA (<1 cm), no dysplasia
5
1+ SSA larger than ≥ 1 cm, no dysplasia
3
1+ SSA with dysplasia, regardless of size
3
1+ TSA
1
Table adapted from the American Gastroenterological Association’s “Guidelines for Colonoscopy
Surveillance after Screening and Polypectomy” (2012)[28]
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Advanced screening techniques such as those that can enhance conventional endoscopy
may be required to enhance screening efficacy and reduce CRC incidence and mortality.
Technological advancement has provided clinicians with a number of tools including narrow
band imaging, high-definition scopes, chromoendoscopy (the use of contrast dye during
endoscopy) and virtual endoscopy (use of sonogram or radiography). All of which have been
used in some clinical capacity but none have become widely used[11].

1.2.2. Interval or ‘post-colonoscopy’ CRC
During the past decade, there has been increased awareness of CRC cases that arise
within the interval between colonoscopies[30,31].

Recently, it was demonstrated that the

adenoma detection rate is inversely associated with these ‘interval’ colorectal cancers (iCRC),
highlighting the importance of thorough index colonoscopies for CRC prevention and its
inherent limitations[30].

As such, screening guidelines are continually reassessed as the

spectrum of colonic polyps becomes more clearly defined, and as predictors for the development
of these polyps are better understood[28].
Polyps contributing to iCRC may have an aggressive biological phenotype (i.e. those
with multiple mutations or with CIMP-H and MSI-H), or are simply missed during screening
colonoscopy, or a combination of both factors. In fact, recent studies have attributed more than
75% of iCRC to factors associated with inadequate colonoscopy rather than the rapid
development of a new cancers,[24,32] highlighting the need for improved endoscopic
observation. The growing consensus is that the majority of iCRC, especially in the proximal
colon,[31,33,34] is the direct result of missed lesions during colonoscopy[24,32,35] as it
inversely correlates with adenoma detection rates[30]. Therefore, in determining the risk factors
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associated with iCRC, it is important to identify those risk factors that may be associated with
the formation of colon lesions that most likely evade detection during colonoscopy.

The underlying pathology of missed precancerous lesions may partially explain why
iCRC arises despite routine colonoscopic surveillance. The flat or depressed morphology of SPs
make them difficult to detect endoscopically[11]. Recently, it was demonstrated that SPs have a
number of additional morphologic characteristics that contribute to their evasiveness, including
the presence of a mucous cap or a rim of debris or bubbles obstructing their detection during
endoscopy[11,12,36]. Moreover, once detected, the sessile nature of these lesions makes their
complete resection using snare polypectomy technically challenging due to the lack of defined
visual borders. These morphological characteristics strongly implicate the presence of SPs,
particularly in the proximal colon, as key contributors to iCRC. Therefore, more reliable
predictors of all polyps, and specifically the serrated polyp subtype, require further investigation.

1.2.2 Risk Factors
Determinants of precursor lesions in the colon are presumably also risk factors for the
development of cancer. Demographic factors including age, gender, and family history have
been established as risk factors for polyps and subsequent cancer development[37]. The impact
of smoking on CRC risk is of particular interest and has been studied for several decades[38].
Early epidemiological studies found conflicting risks from smoking, perhaps complicated by the
particular population under study[39-42]. Overall, smokers have a modestly increased risk of
CRC,[43] and of adenomatous polyps[44]. Importantly, smoking has been reported to be most
strongly associated with the occurrence of serrated polyps[45,46]. Additional lifestyle factors
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significantly increasing an individual’s risk for CRC include alcohol consumption[47],
obesity[48], and red meat consumption[49], among other dietary factors.

From a chemoprevention standpoint, natural agents or drugs may impact individual
cancer risk. For example, aspirin and non-aspirin NSAIDs reduce the risk of CRC[50,51]. and
also the occurrence of polyps[52], protective effects that may be mediated in large part through
inhibition of cyclooxygenase activity[53]. Population-based studies have consistently shown
benefit from long-term NSAID and, specifically, aspirin use for CRC and polyps[54-56].
Treatment of high-risk subjects with NSAIDs, such as ibuprofen, can also change the molecular
features of adenomatous polyps as well[57].

1.3 ABERRANT CRYPT FOCI AS SURROGATE MARKERS OF COLON CANCER
Aberrant crypt foci (ACF) are the earliest morphologically distinct mucosal abnormality,
a subset of which may be precancerous[58]. Endoscopically, ACF are defined as lesions that are
typically flat, but may be depressed or slightly raised, <5 mm in diameter, and upon application
of a contrast dye (e.g. indigo carmine or methylene blue) appear to have enlarged crypts with
oval or slit-like lumens (Figure 3). Microscopically, ACF have multiple distinct pathologies that
resemble those observed in advanced neoplasia[59,60]. They include a dysplastic subtype, most
likely the dysplastic crypt focus as described by Vogelstein; as well as, two hyperplastic
subtypes: serrated, similar to MVHPs, and non-serrated (distended), similar to GCHPs.
Genetically, they share many of genetic abnormalities seen in advanced neoplasia and CRC,
albeit with fewer molecular abnormalities found in a single lesion, consistent with a step-wise
progression to CRC. To understand the earliest stages of CRC initiation, considerable effort has
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Figure 3. Detection of ACF using high-definition chromoendoscopy. The use of contrast dye,
either methylene blue (top) or indigo carmine (bottom) reveals the presence of foci of enlarged
colonic crypts compared to the adjacent colonic epithelium. It is possible to biopsy single ACF
for molecular and pathologic analyses with the use of biopsy forceps as shown by the single red
arrow. In the foreground, (two red arrows) is an unbiopsied ACF, approximately 2 mm in
diameter.
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been focused on placing aberrant crypt foci within the context of both the traditional and serrated
CRC pathways. The proposed role for ACF within CRC tumorigenesis is presented in Figure 4.

ACF were first described in 1987 within the murine colon following treatment with
azoxymethane (AOM), a known colon carcinogen. Foci of aberrant crypts, with larger and
thicker epithelial linings compared to adjacent normal crypts were described, with a multiplicity
that associated directly with sensitivity to AOM and ultimately, tumor development. Upon their
initial observation it was stated that “it will be important to investigate whether or not these
crypts are present in human colons and if they are more frequent in populations possessing a
higher risk for colon cancer than those at a lower risk”.[58] At the time, they were postulated to
be precursors to neoplastic lesions, at least within the murine colon[61]. A timeline of select
findings for ACF is presented in Figure 5.

In 1991, human ACF were described for the first time in surgically resected colons
[62,63]. Following their identification in human colons, it was postulated that “Since aberrant
crypt foci appear to be the earliest identifiable putative precursors of colon cancer, they represent
lesions that can be characterized further for the earliest genetic and biochemical alterations”[64].
This lead to many studies in the field aimed at molecularly characterizing ACF to determine their
role in tumorigenesis. APC and KRAS mutations were among the first gene mutations to be
detected in human ACF supporting their status as putative precursors of colorectal adenomas[6567]. Evidence of microsatellite or genomic instability[68-70] and aberrant promoter methylation
[71,72] has also been found in ACF. In 1997, the first report of ACF being detected
endoscopically was described by Yokota et al.[73] It has been repeatedly demonstrated that in
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Figure 4. Select highlights in the research of ACF between 1987 and 2008.
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ACF are described in murine colon after carcinogen exposure (Bird RP, Cancer Letters)!
The existence of human ACF are first described (Roncucci, Human Pathol; Pretlow TP, Cancer Res)!

APC and KRAS mutations first identified in human ACF (Smith et al., Cancer Res)!
Microsatellite instability in human ACF (Heinen et al., Cancer Res)!
Identification of ACF during screening colonoscopy (Yokota et al., Gastrointest. Endoscopy)!
ACF identified as precursors to adenomas and cancer; first chemoprevention !
trial (NSAIDs) targeting ACF (Takayama et al., New Engl J Med)!
ACF subclassified by oncogenic mutations and histology (Rosenberg et al., Cancer Res)!

Non-dysplastic ACF are not a surrogate endpoint for
recurrent colorectal adenomas (Cho et al., Cancer Prev Res)!

1987! 1991!

1994!

1996!

1998!

2007!

Year!
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2008!

Figure 5. The proposed position of ACF within the pathways to CRC. ACF are the earliest
putative precursor lesions on the pathway to CRC. Dysplastic ACF, or potential
“microadenoma”, most likely precede the formation of a traditional dysplastic adenoma (TA,
TVA, or VA) and may ultimately be the precursors to 75% of CRC. Hyperplastic ACF, of which
both serrated and distended (non-serrated) pathologic variants exist, are proposed precursors for
SPs (HP, SSA, or TSA). It is unclear if hyperplastic ACF continue on to become SPs or
potentially develop dysplasia and form micro-adenomas, as indicated by the dashed arrow.
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Serrated

situ identification of ACF is possible with the use of dye-spray (e.g. indigo carmine or methylene
blue) and magnifying or high-definition scopes (HD Chromoendoscopy)[60,73-75]. Evidence of
BRAF mutations[60,76], the presence of multiple pathologies representative of neoplasia[59,60],
and associations of ACF counts with known CRC risk factors[77] continued to compile over the
decade, supplementing their precancerous potential.

ACF began to be widely used as endpoints in many chemoprevention studies or as
measures of carcinogen exposure in dietary studies. The first study using ACF in a
chemoprevention trial (NSAIDs including sulindac) as surrogate markers for adenomas and
cancer was reported by Takayama et al. in 1998[78]. Many of the subsequent studies using ACF
as endpoints focus on ACF multiplicity within the distal colorectum or the murine colon[79-82].
Despite the numerous evidence-based correlations between precancerous adenomas and CRC
and ACF, their reliability as a biomarker of CRC began to be questioned[83]. One major concern
limiting the acceptance of ACF as a surrogate marker was inter-rater variability and the
overreliance on endoscopic counts of ACF[84]. Some in the field completely dismissed their
utility as an accurate surrogate marker[85,86]; some came to the defense of ACF citing the need
for more research before rendering a verdict on their fate[87,88]. Furthermore, many of the
molecular studies of ACF, despite total colonic surveillance, restricted molecular and pathologic
characterization of ACF to those removed from the distal colorectum.
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1.4 EXPERIMENTAL DESIGN
Specific Aim 1. To determine the risk factors associated with polyp incidence within a central
Connecticut CRC screening practice.
Screening colonoscopy is credited with a subsequent lowering of CRC incidence, yet
despite wide-spread awareness for the benefits associated with regular screening, 180,000
individuals in 2014 will be diagnosed with CRC alone. The unexpected frequency of iCRC
within individuals who have undergone routine screening underscores the inherent limitations of
colonoscopy. There are specific limitations associated with the detection of proximal or serrated
precancerous lesions. Through a retrospective study of a single gastroenterologist’s clinical
practice, a large sample set can be obtained to identify risk factors for polyp incidence and
multiplicity. Furthermore, polyps can be stratified according to their colonic location or
pathology, to determine site and pathway specific risk factors. These data will help provide
clinical evidence used to identify high-risk individuals who may benefit from advanced
endoscopic methods or shortened surveillance intervals to help reduce the incidence of iCRC.

Specific Aim 2. To determine the downstream consequences of early BRAF and KRAS activation
within human ACF.
ACF represent the earliest putative precancerous lesions detectable by endoscopy.
Previous studies have demonstrated a high frequency of hyperplastic ACF that harbor oncogenic
mutations to the KRAS and BRAF oncogenes in the distal colorectum. However, ACF incidence
is significantly higher across the population compared to precancerous polyps and especially
CRC, suggesting that only a subset of ACF have the potential to progress through tumorigenesis.
We hypothesize that ACF differentially activate the downstream MAPK signaling pathway.
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Using an already established repository of ACF biopsy specimens, a nanoproteomic approach
will be developed to quantify ERK1/2 phosphorylation in microdissected ACF with known
BRAF and KRAS mutation status. These data will reveal insight into downstream signaling
consequences of early oncogenic activation and perhaps provide evidence of ACF’s tumorigenic
potential.

Specific Aim 3. To assess the utility of proximal ACF as a surrogate marker of the colonic
mucosa at risk for CRC development.
ACF though widely studied, have rarely been studied in context of colonic location. The
role of Proximal ACF will be assessed through a prospective endoscopic clinical study. Subjects
enrolled in the study will undergo total high-definition chromoendoscopy at John Dempsey
Hospital at the University of Connecticut Health Center. Proximal (cecum to hepatic flexure) and
distal (distal 20 cm) colorectal ACFs will be counted and a subset will be biopsied for
downstream molecular and pathologic characterization. Comprehensive patient demographic
information will also be collected to associate potential risk factors with proximal ACF incidence
and multiplicity. We hypothesize that proximal ACF represent the presence of a field defect
within the colonic mucosa and may be a distinct surrogate marker of CRC risk compared to their
distal counterparts. The clinical study will provide a large sample size to study potential
interactions between CRC risk factors and ACF incidence. In order to molecularly characterize
these ACF, a high-throughput sensitive genetic screen will be developed that is capable of
detecting

somatic

mutations

in

microdissected
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biopsy

specimens.

CHAPTER 2

POLYP OCCURRENCE WITHIN A CENTRAL CONNECTICUT SCREENING
POPULATION1
2.1 Introduction
The goal of this retrospective clinical study was to identify risk factors associated with
polyp number, including those lesions that constitute the evasive subtypes that may contribute to
iCRC within a central Connecticut screening population. The clinical goal was to identify
subsets of the population that would benefit from modified screening intervals or the addition of
enhanced screening techniques, such as high-definition chromoendoscopy, to potentially reduce
the incidence of iCRC.

2.2 Materials and Methods
2.2.1. Patient selection
Patients were identified from an ongoing gastroenterological practice at the University of
Connecticut Health Center (UCHC). This practice draws patients from a catchment area in
central Connecticut, and is well-defined in terms of socioeconomic and other demographic

1

The majority of this work has been submitted for publication in Gut with the title “Impact of Smoking
and Daily NSAID use on Occurrence of Colonic Polyps: Analyses by Location and Pathology"
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variables. Included were all patients undergoing a colonoscopy performed by one experienced
endoscopist (TJD) between January, 2011 and June, 2013. Data was obtained on each patient by
querying the electronic medical record (EMR) and recording results from endoscopy reports,
admitting charts and associated pathology reports. Data was routinely entered into the EMR by
an RN as a direct query to each patient immediately prior to the colonoscopy procedure in a
uniform manner across the GI endoscopy unit. The following items are routinely obtained: age,
gender, ethnicity, height, weight, smoking status, family history (‘hx’ in Tables) of CRC, statins
and aspirin use. Smoking was coded as never, former, and current, and further reduced to
ever/never for the statistical analysis. Subjects with missing variables were excluded from the
analysis (n=67), with the exception of patients with an unknown family history of CRC (n=119)
that were coded as ‘no’. Sensitivity analyses for the family history of CRC parameter showed no
significant changes to the estimate when including these subjects (∆p-value = -0.0004; ∆estimate =
+0.0137) Additionally, it was noted whether the patient was undergoing colonoscopy for cancer
screening purposes, for some indication secondary to preventative cancer screening, or
surveillance colonoscopy. Human subjects approval was obtained from the Institutional Review
Board at UCHC. Due to the risk of bleeding post-polypectomy, it was a priority to accurately
determine NSAID use prior to the procedure. This was determined by asking each patient upon
admission the following set of questions and recording responses in the EMR: 1. “Do you take
aspirin?” 2. “What dose do you take?” 3. “Do you take it every day?” 4. “When did you take it
last?” 5. “Do you take other NSAIDs like Advil, Motrin, Aleve?” If the answer to question 5 is
yes, questions 2-4 were repeated for each additional NSAID.

2.2.2. Colonoscopy procedure
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High-definition colonoscopy was performed using an Olympus PCF-190 endoscope
(Olympus Corp., Center Valley, PA).

A customized magnesium citrate, split-dose bowel

preparation was used, providing excellent visualization of the entire colon in almost all cases.
All procedures were photo-documented and lesion morphology and colonic location carefully
recorded in the endoscopy report prior to removal. Polypectomies were completed using coldsnare in the majority of cases or snare and cautery, if necessary. Propofol was most commonly
used for general anesthesia. The colon was divided into proximal and distal segments at the
splenic flexure, with lesions occurring within the splenic flexure considered to be proximal.
Colorectal polyps were classified according to the Paris-Japanese criteria[89].

Flat, non-

polypoid lesions were classified as such when the width of the polyp was greater than half of the
height[90].

Lesions were retrieved and sent for standard histological assessment by the

Pathology Department at UCHC.

2.2.3. Pathologic analysis
Colonic polyp tissues were collected prospectively at John Dempsey Hospital from
January, 2011 through June, 2013. As described by Bettington et al.[91], only polyps that were
identified during the colonoscopy procedure have been included in the study. Polyp location was
determined from the colonoscopy report and assigned to proximal, distal and rectal positions[91].
Further location details are provided as follows: proximal (cecum, ascending colon, hepatic
flexure, transverse colon, splenic flexure), distal (descending colon, sigmoid colon, rectum).
Polyp diagnoses were based on current WHO criteria[7] for serrated polyps (includes
hyperplastic polyp, sessile serrated adenoma and traditional adenoma) and traditional polyps
(includes low-grade dysplasia lesions: tubular adenoma, tubulovillous adenoma, villous adenoma
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(none in this study) and high-grade dysplasia or “carcinoma-in-situ”). Serrated polyps were
grouped together because of the evolving pathologic recommendations regarding representative
sessile serrated adenoma histology over the last five years[10]. Representative pathologies are
shown in Figure 2. A detailed pathologic discussion of polyp sub-types has been included in the
appendix, based on the WHO classifications[7].

2.2.4. Statistical analysis
For group comparisons, t-test and Cochran-Mantel-Haenszel χ2 test, respectively, have
been conducted for numerical responses (e.g., Age, BMI) and categorical responses (e.g.,
Gender, Smoker, Family History CRC, etc). To uncover the association of potential risk factors
with polyp characteristics, negative binomial regression models were used. Statistical
significance thresholds were defined at p<0.05 for main effects and p<0.1 for interaction terms.
In general, Poisson or negative binomial regression models can be used to analyze count data (=
the number of polyps per subject). However, in the presence of over-dispersion (i.e., the variance
is greater than the mean) as is the case with our data set, the Poisson model is inappropriate due
to the assumption that the mean is equal to the variance.

Therefore, a negative binomial

regression model was used as an alternative, where it is assumed that the mean and variance are
unequal and over-dispersion is accounted for as a parameter in the model.[92] In this study, all
estimated dispersion parameters are significantly larger than zero, thereby validating the use of
negative binomial regression models.

From a clinical perspective, while negative binomial models do not necessarily provide
readily accessible interpretation of odds ratios, they do in fact offer a measure of severity.
32

Individual risk clearly falls within a spectrum and the number of polyps, among other factors, is
an important variable when determining surveillance intervals as described in the American
Gastroenterological Association’s 2012 Guidelines for Surveillance Colonoscopy (Table 1). By
using the negative binomial model, it is possible to distinguish between individuals at lower risk
(less polyps) and those at higher risk (more polyps), while also taking into account the
contribution of other risk factors. However, parallel logistic regression analyses (no polyps vs.
one or more polyps) were also performed to provide clinically interpretable odds ratios. All
analyses were conducted in Statistical Analysis Systems v. 9.4 (SAS 9.4).

2.3 Results
2.3.1. Baseline Characteristics of the Cohort
A total of 1,988 patients underwent colonoscopy over the 30-month study period. Table
2 presents descriptive statistics of the patient population, with and without polyps.

These

subjects had a mean age of 57.6 ± 11.8 years, were primarily Caucasian (79%) and had an
average BMI of 29.4 ± 7.3. The majority of subjects were never smokers (84%) and undergoing
the colonoscopic procedure for screening (76%) rather than surveillance. Twenty-nine percent
were taking statins and 37% were taking an NSAID (85% of whom were taking aspirin). Fifteen
percent of the subjects had a known family history of CRC. Forty-four percent (n = 876) of
patients had at least one detectable polyp identified and removed during the procedure; this is the
widely used Polyp Detection Rate (PDR). The PDR depends upon at least two important
considerations; quality of the colonoscopy and true prevalence of polyps in the specific patient
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Table 2. Comparison of characteristics for the patients with and without polyps.

Variable
Age, mean (SD)
Gender, n (%)
Male
Female
Smoker, n (%)
Never
Ever
BMI, mean (SD)
Family History of CRC, n (%)
No
Yes
Indication, n (%)
Screening
Surveillance
Statin User, n (%)
No
Yes
Daily NSAID User, n (%)
No
Yes, 81 mg Dose Aspirin
Yes, >81 mg Dose Aspirin
Yes, Other NSAID
†

Patients
Total
(n = 1988)
57.6 (11.8)

No Polyps
(n = 1112)
56.1 (12.7)

≥1 Polyp
(n = 876)
59.6 (10.4)

980 (49)
1008 (51)

504 (51.4)
608 (60.3)

476 (48.6)
400 (39.7)

0.0001

1660 (84)
328 (16)
29.4 (7.3)

960 (57.8)
152 (46.3)
29.1 (7.8)

700 (42.2)
176 (53.7)
29.7 (6.5)

0.0001

1691 (85)
297 (15)

961 (56.8)
151 (50.8)

730 (43.2)
146 (49.2)

0.0553

1505 (76)
483 (24)

890 (59.1)
222 (46.0)

615 (40.9)
261 (54.0)

0.0001

1413 (71)
575 (29)

827 (58.5)
285 (49.6)

586 (41.5)
290 (50.4)

0.0003

1427 (72)
473 (24)
63 (3)
25 (1)

807 (56.6)
256 (54.1)
35 (55.6)
14 (56.0)

620 (43.4)
217 (45.9)
28 (44.4)
11 (44.0)

0.4996

†

P value

0.0001, t-test

0.0571, t-test

Denotes Cochran-Mantel-Haenszel χ2 test statistic, unless otherwise noted

34

population being examined; 46% is typical in high quality settings[93].

Recently, it was

demonstrated that the adenoma detection rate is inversely associated with iCRC, highlighting the
importance of thorough index colonoscopies for CRC prevention[30].

2.3.2. Predictors of Total Polyp Number and Identification of a Smoking/Aspirin interaction
A group of eight variables was included in the negative binomial regression model for
total number of detected polyps in each patient: age, gender, smoking, BMI, family history of
CRC, indication (screening vs. surveillance), statin use and daily NSAID use. One of the
primary objectives in this inquiry was the potential association of smoking with polyp
occurrence, and whether other factors might modify any association. We therefore included
interaction terms for smoking with each of the other 7 variables in separate models. Only one
model yielded a statistically significant interaction with smoking, and that was daily NSAID use
(p=0.0355) (Table 3).

Daily NSAID users included in the previous model reported use of any NSAID daily
regardless of type or dose; therefore, daily NSAID users were separated into daily aspirin users
(95% of daily NSAID users) and daily other NSAID users (Table 4). The statistical analysis
revealed that seven variables [age, gender, smoking history (all p<0.0001); BMI, family history
of CRC, indication (all p<0.01); and statin use, p=0.0313] were significantly associated with
increased polyp number, and one, daily aspirin use (p<0.01), was significantly associated with
reduced polyp number (Table 4). Daily use of other NSAIDs was not significantly associated
with polyp number (p=0.7145). Importantly, the smoking interaction with daily aspirin use
remained significant at alpha = 0.10 (p=0.0795).
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Table 3. Negative binomial model of total polyps with grouped daily NSAIDs.
Variable
Age
Gender (M)
Smoker (Ever)
BMI
Family History CRC (Y)
Indication (Surveillance)
Statin User (Y)
Daily NSAID User (Y)
Smoking*Daily NSAID User

Estimate (95% CL)
0.03 (0.02, 0.03)
0.35 (0.22, 0.48)
0.52 (0.33, 0.70)
0.01 (0.003, 0.02)
0.30 (0.13, 0.47)
0.23 (0.08, 0.38)
0.16 (0.01, 0.30)
-0.23 (-0.40, -0.07)
0.40 (0.03, 0.77)

S.E.
0.003
0.07
0.09
0.005
0.09
0.07
0.08
0.09
0.19

P value
<0.0001
<0.0001
<0.0001
0.0079
0.0006
0.0016
0.0391
0.0064
0.0355

(*)
***
***
***
***
***
***
**
***
**

Intercept = -2.48 (-2.97, -1.98), SE = 0.25, p<0.0001; Dispersion = 0.77 (0.63, 0.94), SE = 0.08
* = 0.05≤ p <0.10; **= 0.01≤ p <0.05; ***= p < 0.01
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Table 4. Negative binomial model of total polyps.
Variable
Age
Gender (M)
Smoker (Ever)
BMI
Family History CRC (Y)
Indication (Surveillance)
Statin User (Y)
Daily Aspirin User (Y)
Daily Other NSAID User (Y)
Smoking*Daily Aspirin User
Smoking*Daily Other NSAID User

Estimate (95% CL)
0.03 (0.02, 0.03)
0.34 (0.21, 0.48)
0.52 (0.33, 0.70)
0.01 (0.003, 0.02)
0.30 (0.13, 0.47)
0.24 (0.09, 0.38)
0.16 (0.01, 0.31)
-0.24 (-0.40, -0.07)
-0.14 (-0.86, -0.59)
0.35 (-0.04, -0.74)
0.72 (-0.44, 1.89)

S.E.
0.003
0.07
0.09
0.005
0.09
0.07
0.08
0.09
0.37
0.20
0.60

P value
<0.0001
<0.0001
<0.0001
0.0083
0.0005
0.0015
0.0313
0.0059
0.7145
0.0795
0.2237

(*)
***
***
***
***
***
***
**
***
*

Intercept = -2.48 (-2.97, -1.98), SE = 0.25, p<0.0001; Dispersion = 0.77 (0.63, 0.94), SE = 0.08
* = 0.05≤ p <0.10; **= 0.01≤ p <0.05; ***= p < 0.01
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To illustrate the impact of the smoking and aspirin interaction, the predicted number of
polyps from the model is shown in Figure 6; among non-smokers, aspirin use significantly
reduces the expected number of polyps, whereas among ever smokers, aspirin use significantly
increases the expected number of polyps. Logistic regression models of the population of
subjects with no polyps versus those with one or more polyps reveal statistically significant odds
ratios for all variables (p<0.05) with the exception of statin use (p = 0.1434) (Figure 7). Subjects
who smoke and use aspirin daily are significantly more likely to have polyps than those who do
not smoke and do not take aspirin (OR = 2.1 [95% CI: 1.2,3.8]). Non-smokers who take aspirin
regularly are less likely to have polyps (OR = 0.7 [95% CI: 0.5-0.9]), while smokers who do not
take aspirin are more likely to have polyps (OR =1.6 [95% CI: 1.2-2.1]).

2.3.2. Predictors of Polyp Colonic Location and Pathology
The location and pathology of polyps are important both in terms of malignant potential
andlikelihood to evade detection. Each polyp’s colonic location and underlying pathology was
carefully recorded (Table 5). The distribution of polyps by location in proximal or distal colon
(Table 6, Cochran-Mantel-Haenszel χ2 = <0.0001) and by serrated or traditional pathologies
(Table 7, Cochran-Mantel-Haenszel χ2 = 0.6518) was also recorded. In order to determine
location and pathology specific risk factors, we applied the same negative binomial regression
models to distal and proximal polyps separately, and to serrated and traditional polyps separately
(Tables 8 and 9, respectively).

A summary of these findings (Table 10) shows that smoking is significantly associated
with the occurrence of both serrated and traditional subtypes, and with polyps found in proximal
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Figure 6. Expected total number of polyps by gender, smoking history, and daily aspirin
use illustrate smoking and aspirin interaction. Using negative binomial modeling (Table 4),
expected number of polyps are generated according to gender (female, left; male right), smoking
status (non-smokers, blues; smokers, reds) and aspirin use (non-users, light colors; daily users
dark colors). Other variables were kept constant at baseline or average value: Age = 57 yrs; BMI
= 29; Family History of CRC = No; Indication = Screening; Statin Use = No.
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Expected Number of Polyps

2.0

1.5
Smoker (-) / Daily Aspirin (-)
Smoker (-) / Daily Aspirin (+)
Smoker (+) / Daily Aspirin (-)
Smoker (+) / Daily Aspirin (+)

1.0

0.5

0.0

Female

Male
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Figure 7. Odds ratios generated from logistic model of polyp occurrence confirm smoking
and aspirin interaction. Logistic modeling for polyp occurrence (individuals with no polyps
versus those with one or more polyp) reveal significant ORs (p < 0.05) for all risk factors with
the exception of statin use, including the interaction between smoking and aspirin as revealed by
negative binomial model. ORs are representative of listed unit changes for continuous variables
and listed category for categorical variables. Boxed numbers appearing on the graph represent
calculated OR and the respective 95% confidence limits.
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1.3 (1.2, 1.5)

Age (Unit = 10)

1.5 (1.2, 1.8)

Gender (M vs. F)

1.1 (1.01, 1.2)

BMI (Unit = 5)
Family Hx of CRC (Y vs. N)

1.3 (1.01, 1.7)

Indication (Surv. vs. Screen)

1.4 (1.1, 1.7)
1.2 (0.9, 1.5)

Statin Use (Y vs. N)
Non-smoker/Daily Aspirin Use a

0.7 (0.5, 0.9)

Smoker/No Daily Aspirin Use a

1.6 (1.2, 2.1)

Smoker/Daily Aspirin Use a

2.1 (1.2, 3.8)

0

1

2
Odds Ratios

a Referent: Non-smoker, No

Daily Aspirin Use
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3

4

Table 5. Distribution of polyp pathologies. Number of polyps (number of subjects with polyps)

Location
Proximal
Colon
Distal
Colon

Serrated Polyps
Sessile
Traditional
Hyperplastic
Serrated
Serrated
Polyps
Adenomas Adenomas

Traditional Polyps
Tubular
Adenomas

Tubulovillous
Adenomas

Carcinomain-situ

118 (103)

56 (47)

0

545 (365)

7 (7)

8 (6)

238 (181)

38 (31)

0

318 (252)

11 (10)

13 (7)
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Table 6. Distribution of polyps by location. Proximal and distal location are not independent
(CMH χ2 = <0.0001)

Proximal
Polyps

Frequency
0
1
2
3
4
≥5
Total

0
1118
250
63
30
8
1
1470

1
230
86
29
9
3
4
361

Distal Polyps
2
3
65
13
30
8
8
10
5
1
3
0
1
0
112
32
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4
4
2
0
1
0
0
7

≥5
4
1
0
1
0
0
6

Total
1434
377
110
47
14
6
1988

Table 7. Distribution of polyps by pathway. Serrated and traditional pathways are independent
(CMH χ2 = 0.6518)

Serrated
Polyps

Frequency
0
1
2
3
4
≥5
Total

0
1207
178
40
11
3
3
1442

1
279
35
10
5
3
1
333

Traditional Polyps
2
3
105
45
19
7
0
3
1
0
0
0
0
0
125
55
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4
15
2
2
0
0
0
19

≥5
13
0
1
0
0
0
14

Total
1664
241
56
17
6
4
1988

Table 8. Negative binomial models of proximal and distal polyps. (* = 0.05 ≤ p < 0.10; **= 0.01 ≤ p < 0.05; ***= p<0.01)

Variable
# Distal Polyps
Age
Gender (M)
Smoker (Ever)
BMI
Fam Hx CRC (Y)
Indication (Surveillance)
Statin User (Y)
Daily Aspirin (Y)
Daily Other NSAID (Y)
Smoking*Aspirin
Smoking*Other NSAID
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Proximal Polyps*
Estimate (95% CL) S.E.
0.25 (0.15, 0.35)
0.03 (0.02, 0.04)
0.24 (0.06, 0.41)
0.34 (0.10, 0.60)
0.002(-0.01, 0.01)
0.37 (0.14, 0.59)
0.20 (-0.005, 0.39)
0.25 (0.06, 0.44)
-0.19 (-0.41, 0.04)
0.07 (-0.83, 0.96)
0.06 (-0.47, 0.60)
0.74 (-0.71, 2.18)

0.05
0.004
0.09
0.13
0.01
0.11
0.10
0.10
0.11
0.49
0.27
0.74

P value (*)

Variable

<0.0001
<0.0001
0.0077
0.0065
0.7415
0.0012
0.0445
0.0118
0.0990
0.8804
0.8141
0.3174

# Proximal Polyps

***
***
***
***
***
**
**
*

Distal Polyps†
Estimate (95% CL) S.E.
0.22 (0.13, 0.31)
0.02 (0.01, 0.02)
0.38 (0.20, 0.55)
0.59 (0.35, 0.82)
0.02 (0.01, 0.03)
0.19 (-0.04, 0.42)
0.25 (0.06, 0.45)
0.02 (-0.18, 0.22)
-0.21 (-0.44, 0.02)
-0.62 (-1.84, 0.61)
0.46 (-0.03, 0.95)
0.52 (-1.22, 2.26)

*Intercept = -3.00 (-3.65, -2.34), SE = 0.33, p<0.0001; Dispersion = 1.07 (0.83, 1.39), SE = 0.14
†Intercept = -2.98 (-3.63, -2.32), SE = 0.33, p<0.0001; Dispersion = 0.92 (0.67, 1.25), SE = 0.15

0.05
0.004
0.09
0.12
0.01
0.12
0.10
0.10
0.12
0.62
0.25
0.89

P value (*)
<0.0001
0.0005
<0.0001
<0.0001
0.0014
0.1059
0.0111
0.8303
0.0779
0.3247
0.0630
0.5576

***
***
***
***
***
**
*
*

Table 9. Negative binomial model of serrated and traditional polyps (* = 0.05 ≤ p < 0.10; **= 0.01 ≤ p < 0.05; ***= p<0.01)

Parameter
# Trad. Polyps
Age
Gender (M)
Smoker (Ever)
BMI
Fam Hx CRC (Y)
Indication (Surveillance)
Statin User (Y)
Daily Aspirin (Y)
Daily Other NSAID (Y)

Serrated Polyps*
Estimate (95% CL) S.E.
-0.02 (-0.15, 0.10)
0.01 (-0.004, 0.02)
-0.003 (-0.24, 0.23)
0.71 (0.43, 0.99)
0.02 (0.004, 0.04)
0.27 (-0.04, 0.58)
0.25 (-0.02, 0.52)
-0.05 (-0.32, 0.23)
-0.15 (-0.34, 0.23)
-1.74 (-3.81, 0.33)

0.06
0.01
0.12
0.14
0.01
0.16
0.14
0.14
0.15
1.06

P value (*)

Parameter

0.7003
0.1890
0.9821
<0.0001
0.0170
0.0850
0.0689
0.7468
0.7211
0.0995

# Serrated Polyps

***
**
*
*

*

Traditional Polyps†
Estimate (95% CL) S.E.
-0.01 (-0.15, 0.13)
0.04 (0.03, 0.05)
0.56 (0.38, 0.74)
0.51 (0.28, 0.74)
0.01 (-0.004, 0.02)
0.27 (0.04, 0.51)
0.27 (0.08, 0.48)
0.25 (0.05, 0.45)
-0.24 (-0.45, -0.03)
0.58 (-0.09, 1.25)

*Intercept = -2.75 (-3.62—-1.88), SE = 0.44, p<0.0001; Dispersion = 2.31 (1.73−3.08), SE = 0.34
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†Intercept = -3.81 (-4.51—-3.11), SE = 0.36, p<0.0001; Dispersion = 1.44 (1.16-1.79), SE = 0.16

0.07
0.005
0.09
0.13
0.01
0.12
0.10
0.10
0.11
0.34

P value (*)
0.8681
<0.0001
<0.0001
<0.0001
0.1802
0.0220
0.0057
0.0130
0.0275
0.0907

***
***
***
**
***
**
**
*

Table 10. Summary of significant risk factors according to polyp pathology and location.

Risk Factor
Age
Male
Ever-smoker
BMI
Family History of CRC
Undergoing Surveillance Colonoscopy
Statin User
Daily Aspirin User
Daily Other NSAID User
Smoking * Daily Aspirin User
Smoking * Daily Other NSAID User

+/−
+
+
+
+
+
+
+
−
NS
+
NS

Total
Polyps
***
***
***
**
***
***
**
***

Proximal
***
***
***

Location
Distal
***
***
***
***

***
**
**
*NS

*
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NS = Not significant (* = 0.05 ≤ p < 0.10; **= 0.01 ≤ p < 0.05; ***= p<0.01)

**
*NS
*

Pathology
Serrated
Traditional
***
***
***
***
**
*NS
**
*NS
***
**
**
*NS

as well as distal colon (all p<0.0001). The interaction effect between smoking and aspirin use
was only observed among distal polyps (p=0.0630). Neither smoking interaction term (aspirin or
other NSAID) was significant (p>0.10) in the pathology models so the parameters were excluded
from these analyses. In our patient population, males were at greater risk of distal and traditional
polyps than females (p=<0.0001 for both). The number of traditional polyps increased with age
(p<0.0001) in both the distal (p=0.0005) and proximal colon (p<0.0001), but not in the serrated
polyp group (p=0.1890).

BMI was associated with distal location (p<0.01) and serrated

histology (p=0.01). The opposite is true for family history of CRC which was only associated
with proximal location (p<0.01) and traditional histology (p<0.05). Surveillance colonoscopy
was a significant predictor of polyps in both colon locations(both p<0.05) and was specifically
associated with traditional polyps (<0.01).

In addition to the eight explanatory variables for analysis of pathology and location
(Tables 8 and 9), we included in the model for each location the number of polyps in the other
location (i.e., the model for proximal location included the number of distal polyps), and in the
model for each pathology, the number of polyps of the other pathology was included. We found
that number of proximal polyps was a significant predictor of the number of distal polyps
(p<0.0001) and vice versa (p<0.0001) (Tables 6 & 8). However, the number of serrated polyps
was not a predictor of the number of traditional polyps, nor was the reverse true (Tables 7 & 9).
Statin use was associated with traditional polyp occurrence (p=0.0130), but not serrated, and
with proximal location (p=0.0181) but not distal.
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2.4 Discussion
The primary goal of this study was to identify risk factors associated with colon polyp
number within a typical screening population. Secondary to this goal was the identification of
risk factors of specific polyp pathology and location that may contribute to risk of developing
iCRC. In this cross-sectional study of 1,988 colonoscopy patients, it was found that the total
number of colon polyps was associated with male gender, smoking, BMI, and family history of
CRC, and inversely with daily aspirin use, consistent with previous studies.[37,52,56] A direct
association of statin use and polyp number was observed. The relationship of statin use and
colonic polyps has been inconsistent in the literature, with some published studies reporting a
protective effect of statins,[94-96] whereas other studies indicate little to no effect[97-100] and
even a potentially harmful effect.[101]

Among those factors examined, only smoking was associated with proximal location and
serrated morphology, the type of polyp most likely to be missed upon endoscopic
examination.[31,102] Interestingly, the number of distal colon polyps of any pathology predicted
the presence of proximal polyps in our study sample. However, the presence of one subtype
(serrated or traditional) did not predict the presence of the other form of polyp. Dodou and de
Winter (2012) conducted a meta-analysis of 32 studies and found that any type of distal lesion
predicted increased risk for a proximal lesion,[103] consistent with our observation with respect
to large intestinal location.

There have been a number of studies that have examined the relationship of daily NSAID
or aspirin use[52,54-56,104] or of smoking[38,43,44] with the development of colon polyps, but
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only recently has the possible interaction of these two important modifiers been described.[105]
As recently reported by Ishikawa et al. (2014), the use of baby aspirin in a high-risk Asian
population resulted in an increased risk of CRC recurrence in active smokers. Although the
findings were post hoc, the interaction of smoking with any NSAID use in the present study was
very strong, and remained significant when specifically examining aspirin use, which is
consistent with the recent results from Japan.[105] The data suggest that the interaction may be
limited specifically to aspirin, but additional subjects who regularly take non-aspirin NSAIDs
such as ibuprofen would be required to test these potential interactions. In addition, our study
population was not confined to those patients at high-risk for CRC, nor weighted towards
surveillance colonoscopies, and the effect was seen in subjects with any history of smoking
(rather than only active smokers), adding additional broad applicability to our results. If this
finding is confirmed, it has important implications especially for active smokers, a population
that still comprises approximately 20% of the adult population in the United States, but also
potentially for those who have quit smoking. A mechanism to explain how smoking could alter
so dramatically the effect of daily aspirin use on development of polyps is not readily apparent.
While speculative, it is possible to envision a potential synergistic relationship between smoking
and the negative side effects of habitual aspirin intake in some individuals that may result in
increased mucosal injury. Additional molecular studies are needed to clarify these important
relationships.

In summary, the strengths of this study include a patient base from one gastroenterologist
at an academic hospital in a relatively stable population of central Connecticut over a welldefined period of time. The polyp detection rate is consistent with those widely reported by
51

other institutions.[30,93] and several of the epidemiological findings are consistent with results
already reported in the literature, including the recently reported interaction between cigarette
smoking and baby aspirin use. In addition, several new and significant findings in this study
contribute to our progress on understanding the predictors and risk factors for colonic polyps,
and therefore colon cancer risk in general. A potential limitation is that the patient population is
‘real-world’ and not part of an existing research study per se; however, this may also be viewed
as a key strength of this study. These results, combined with previous studies, provide
information that may facilitate the identification of subjects who would benefit most from the
application of shorter screening intervals or modified endoscopic procedures, such as intensive
bowel preparation,[106] increased withdrawal time,[107] or the use of high-definition
chromoendoscopy[75].

With careful consideration of risk factors discussed in this study,

gastroenterologists may see increases in both their proximal adenoma and serrated polyp
detection rates and subsequently a decrease in the incidence of interval colon cancers. Finally,
we believe that the strong effect modification we observed, in which daily aspirin intake among
non-smokers protected against the formation of polyps in a dose-dependent manner, yet
increased polyp numbers among ever smokers, is of significant concern and should be
investigated in further studies.
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CHAPTER 3

MAPK SIGNALING CONSEQUENCES OF RAF AND RAS ACTIVATION IN
HUMAN ABERRANT CRYPT FOCI2
3.1 Introduction
While significant advances have been made in our understanding of the molecular events
that accompany the progression of normal colonic mucosa to adenocarcinomas, the precise role
of ACF within the adenoma-carcinoma sequence has not yet been conclusively established.
Identifying genetic and molecular abnormalities that may contribute to their formation and
expansion within the colonic mucosa are necessary for establishing their utility as surrogate
cancer markers. As it has been previously reported [60], ACF from the distal colorectum almost
always show histological features of hyperplasia, and these lesions often harbor somatic
mutations to key proto-oncogenes, including BRAF and KRAS. Because of their limiting sample
size, however, molecular characterization of ACF has proven to be technically challenging
beyond the available routine histological and immunohistological analyses.
An ultra-sensitive platform for protein quantification has been developed that enables
capillary-based nanofluidic isoelectric focusing and antibody-based chemilluminescence
analyses on only nanogram quantities of total protein[108].

2

This nanofluidic proteomic

The majority of this work has been previously published in Proteomics (vol. 13; issue 9; pages 14281436) in December 2013 with the title “Nanoproteomic analysis of extracellular receptor kinase-1/2 posttranslational activation in microdissected human hyperplastic colon lesions" (PMID:23467982)
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immunoassay (NIA) has been used primarily to examine changes in signaling activity in
response to drug treatment [109,110]. To date, however, these applications have relied primarily
on whole tissue or cell culture lysates[111]. Since it is impossible to generate a sufficient
concentration of protein lysate from small (< 1mm2) biopsy specimens for traditional
IEF/Western blotting, we developed a new methodology combining the use of tissue
microdissection with nanofluidics to study protein modifications in limiting numbers of cells.

In the following study, we demonstrate the use of NIA to examine the downstream
consequences of RAS and RAF activation in ultraviolet-infrared (UV/IR) captured ACF
removed from normal human colonic mucosa during screening colonoscopy. We have examined
the phosphorylation states of ERK1 and ERK2 in UV/IR microdissected ACF and adjacent
normal colonic mucosa.

The significance of this experimental approach is that we can

quantitatively determine the levels of individual ERK isoforms within the cellular context of
oncogenic mutations.

3.2 Materials and Methods
3.2.1. Subject selection
All patients included in this study underwent a total colonoscopy at the University of
Connecticut Health Center (UCHC) at John Dempsey Hospital (JDH) in accordance with
Institutional policies. All patients who met the Amsterdam criteria for familial adenomatous
polyposis (FAP) or hereditary non-polyposis CRC (HNPCC) were excluded from this study.
This study was performed following Institutional Review Board approval and after receiving
written informed consent from the subjects.
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3.2.2. ACF collection and characterization
ACF were identified and isolated from grossly normal-appearing colonic mucosa by
biopsy in situ during high-resolution, close-focus magnifying chromoendoscopy as previously
described [60]. Briefly, the distal 20-cm of the colorectum (encompassing parts of the rectum
and sigmoid colon) were stained with 40 mL of 0.2% indigo carmine. ACF were visualized and
photographed using an Olympus close-focus colonoscope (XCF-Q160ALE; Olympus Corp.,
Center Valley, PA) capable of 60x magnification over a longer visualizing distance (100 mm).
A finding was accepted as an ACF if, under magnification, two or more crypts had increased
lumen diameter, thick crypt walls or abnormally shaped lumens. Biopsies of individual ACF and
normal mucosa were immediately embedded in optimum cutting temperature (OCT) freezing
medium, flash-frozen, and stored at -80°C.

Histological analyses were performed on coded hematoxylin and eosin (H&E) stained
sections using light microscopy by T.V.R, a board-certified human pathologist who was blinded
to clinical and molecular findings, according to previously described characteristics [60].
Briefly, hyperplastic ACF are characterized by the same criteria applied to hyperplastic polyps
[112].

Serrated hyperplastic ACF are defined by their stellate luminal shape (serrated on

oblique or cross-section) and the prominent component of columnar cells with microvesicular
cytoplasm. Distended hyperplastic ACF lack crypt serration and have prominent goblet cell
populations. In addition, hyperplastic ACF frequently have tufting of the surface epithelium.
H&E slides were visualized using a BX60 upright bright-field microscope with 10x occulars/20x
UPlanFl objectives (Olympus), a CoolSNAP imager and RSImage software, v.1.9.2
(RoperScientific, Ottobrunn, Germany)
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3.3.3. Laser capture microdissection, DNA extraction and mutation analyses for BRAFV600E
and KRAS codons 12/13
Laser capture microdissection, DNA extraction and subsequent analyses for mutations to
BRAF and KRAS were performed as previously described [60,112].

Briefly, frozen serial

sections of ACF were prepared at 5- to 7-µm thickness on glass slides and microdissection was
performed on these sections using the Veritas microdissection instrument (Applied Biosystems,
Inc., Foster City, CA). Whenever possible, cells from the adjacent normal mucosa (ANM)
directly abutting the aberrant crypts were collected separately by laser-capture. On average,
approximately 3,000 cells were collected from each sample.

DNA (25 ng) was extracted from micro-dissected aberrant crypts and ANM using the
PicoPure DNA Extraction Kit (Applied Biosystems). Mutations were detected by amplifying a
189-bp fragment of the BRAF gene spanning codon 600 using the following primers: forward,
5’-CCTAAACTCTTCATAATGCTTGCTC-3’

and

reverse,

5’-

CCACAAAATGGATCCAGACA-3’. Similarly, a 205-bp fragment of KRAS spanning codons
12

and

13

was

amplified

GTACTGGTGGAGTATTTGAT-3’

using
and

the
reverse,

following

primers:

forward,

5’-

5’-TCTATTGTTGGATCATATTC-3’.

Amplified products were confirmed by gel electrophoresis and enzymatically purified with 2 µL
of EXO SAP-IT (U.S. Biochemical Corp., Cleveland, OH). 2.5-µL aliquots of product were
sequenced using the forward primer with an ABI BigDye TerV3.1 Cycle Sequencing kit on an
ABI 9700 thermocycler (Applied Biosystems). Fifteen microliters of ethanol-precipitated
reaction product was sequenced by capillary electrophoresis using a 3100-avant Genetic
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Analyzer (Applied Biosystems). The data were analyzed using ABI DNA Sequencing Analysis
Software (ver. 3.7). Positive controls for BRAF (human colon carcinoma sample with a known
mutation at codon 600) and KRAS (SW480 cells) and a negative control (placental DNA; Sigma,
St. Louis, MO) were used in these analyses.

3.3 Results
3.3.1. KRAS and BRAF mutational status in ACF
172 distal colon ACF were stratified according to their molecular genotype into the
following three categories: KRAS, BRAF, or wild-type for both loci (referred to as WT). ACF
were independently classified as hyperplastic-serrated or hyperplastic-distended (Figure 8).
Approximately half (51%) of distended ACF exhibit a missense mutation in the KRAS gene at
either codon 12 or 13 (Table 11). Interestingly, the presence of a BRAF mutation in distended
ACF is rare (3%) and 31% of distended ACF are WT for both KRAS and BRAF. These results
correlate with our previously reported frequencies for distended crypts (KRAS: 42%; BRAF:
3%; WT 55%)[60]. In comparison, a large percentage of serrated ACF harbor a BRAFV600E
mutation (36%) consistent with our previous results[60]. However, the frequency of KRAS
mutations in serrated ACF (40%) is greater than we previously reported (19%)[60]. In addition,
the frequency of specific KRAS missense mutations, including G12A, G12C, G12D, G12V, and
G13M, occur at equivalent frequencies between serrated and distended ACF, with G12D being
the predominant mutation (Table 11).

57

Figure 8: Experimental approach for NIA analysis of microdissected ACF. The combined
use of UV/IR microdissection with NIA increases the informative potential of size-limited
human biopsy specimens. The use of fresh-frozen tissues, cryosectioning and microdissection
enables the acquisition of histological, genetic and proteomic data. Histopathological scoring
shows H&E staining of representative normal colonic mucosa, distended and serrated
hyperplastic ACF (all images shown at 200x magnification).
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Table 11. BRAF and KRAS mutation frequency in distal hyperplastic ACF.

Hyperplastic ACF
Mutation
Status
Wild-Type
KRAS

BRAF

Mutation

Distended
(%)(n = 67)

Serrated
(%)(n = 105)

N/A

31 (46.27)

22 (20.95)

G12A

1 (1.49)

0

G12C

4 (5.97)

2 (1.90)

G12D

16 (23.88)

26 (24.76)

G12V

12 (17.91)

16 (15.24)

G13M

1 (1.49)

0

ALL

34 (50.75)

44 (41.90)

V600E

2 (2.99)

39 (37.14)
TOTAL ACF = 172
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3.3.2. MAPK activation in ACF
Based on our findings of a distinct ACF histology that is related to the underlying
oncogenic alterations, we hypothesized that KRAS or BRAF mutations may be associated with
differential ERK-1/2 activation. In order to test this hypothesis, a pan-ERK1/2 antibody was
examined in frozen tissue sections. As shown in Figure 9, ACF displayed a modestly elevated
nuclear accumulation of ERK1/2 compared to adjacent NCM. However, immunostaining was
highly variable across the panel of ACF that were tested, compromising our ability to quantify
the staining intensity. Thus to more accurately assess the potential differential activation of ERK
signaling in these hyperplastic lesions, we developed a new method combining the high cellular
resolution of tissue microdissection with the sensitivity afforded by a nanofluidic proteomic
immunoassay. Our initial approach was to optimize the microdissection method to maximize
protein yield. It was determined that the use of UV/IR microdissection followed by an on-cap
protein extraction in limited sample buffer was essential (Figure 8).

Furthermore, we

determined that the lower limit of detection is 12 ng of total protein for the NIA analysis,
requiring at least 1 mm2 of captured tissue from 12-µm sections.

Using this approach, the relative concentrations of unphosphorylated ERK-1 and -2,
singly phosphorylated ERK-1 and -2 (pERK1/2), and the activated dually phosphorylated ERK-1
and -2 (ppERK1/2) isoforms were measured in ACF. HeLa cell lysates were used as controls to
determine the relative pIs of the individual isoforms: ERK1 = 5.78 ± 0.059; pERK1 = 5.42 ±
0.059; ppERK1 = 5.10 ± 0.059; ERK2 = 6.50 ± 0.059; pERK2 = 6.03 ± 0.059; ppERK2 = 5.55 ±
0.059. As shown in Figure 10, colon crypts isolated from adjacent normal mucosa (N=8)
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Figure 9. ERK1/2 analysis in human colonic mucosa.

Immunofluorescence analysis of

ERK1/2 was determined in frozen tissue sections as described under Materials and methods.
ACF show evidence of nuclear accumulation of ERK1/2 (white arrowheads) suggesting its
activation compared to normal colonocytes (200x). Blue, DAPI nuclear stain (1:10,000); Green,
1° mouse mAb anti-human β-catenin for membrane visualization (Sigma, 1:1,000), 2° Alexa 488
goat anti-mouse IgG (Invitrogen, 1:200). Red, 1° rabbit pAb anti-human ERK1/2 (Novus, 1:200),
2° Alexa 568 goat anti-rabbit IgG (Invitrogen, 1:200). Rabbit IgG Isotype control shows no
positive staining (data not shown).
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SERRATED ACF DISTENDED ACF

NORMAL

DAPI
ERK 1/2
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MERGE

Figure 10. ERK activation state in normal colonocytes. Microdissected colonocytes were
prepared from frozen sections as described under Materials and methods. Normal-appearing
crypts were microdissected from distant normal biopsies (gray) and from adjacent normal areas
within

ACF

biopsies

(blue)

and

subjected

to

NIA

analyses.

A)

Representative

electrophoretograms of ERK1/2 isoforms. B) Electrophoretograms were quantified for ERK1/2
phosphoforms using Compass software to measure the area under the curve. There are no
significant differences in ERK activation between normal crypts according to their proximity to
hyperplastic crypts. Error bars represent one standard deviation of the mean.
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showed no significant differences in the extent of ERK activation when compared to colonocytes
prepared from independent biopsy specimens histologically confirmed as normal mucosa (N=6).

While a total of 172 ACF were used for the mutational analysis, a subset of 32 samples
were sectioned and analyzed for ERK activation status using the NIA. The subset was chosen so
as to maximize the use of the most recently obtained human tissues, thus minimizing the extent
of protein degradation during sample storage. Of the 32 specimens that were selected, 20 were
determined to provide a sufficient quantity of protein for the NIA analysis. Ultimately,
colonocytes were micro-dissected from four ACF biopsies that were wild-type for BRAF and
KRAS mutations, nine ACF positive for KRAS codon 12 or 13 mutation, and seven ACF positive
for the BRAFV600E mutation.

Samples were analyzed for ERK activation signatures and

compared to colonocytes isolated from adjacent normal mucosa Figure 11.

Relative

concentrations of activated ERK 2 are significantly elevated in all ACF compared to normal
crypts. However, only KRAS and WT ACF have significantly increased ERK1 activation. Distal
colon ACF with constitutively activated KRAS activate ERK1/2 to the greatest extent, suggesting
that these mutations are a more potent activator of the MAPK signaling cascade compared to the
BRAFV600E mutation.

3.4 Discussion
The 'classical pathway' of colon carcinogenesis describes the step-wise formation of CRC
resulting from the accumulation of genetic mutations, specifically those occurring within the
APC, KRAS, and p53 genes[3,113]. An alternative pathway that has been refined over the past
decade results in a spectrum of hyperplastic lesions, ranging
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Figure 11. ERK activation state in ACF. Microdissected colonocytes were prepared from
frozen sections as described under Materials and methods. Nanofluidic proteomic immunoassays
for ERK1/2 result in distinct electrophoretogram signatures (A,C,E) for ACF when compared
with adjacent normal crypts (purple). Signatures shown represent three ACF genotypes: WT for
BRAF/KRAS (A, green), KRAS mutant (C, blue), and BRAF mutant (E, red). Areas under the
curve for each ERK1 and ERK2 phosphoform are quantified as a percent of the total ERK1 or
ERK2 (B,D,F). Only WT for BRAF/KRAS ACF (B) and KRAS mutant ACF (D) have
significantly elevated levels of pERK1 and ppERK1, while BRAF mutant ACF (F) have only
slightly elevated (not significant) pERK1 and ppERK1 levels. All ACF significantly activate
ppERK2. **: Significant using Tukey’s HSD procedure, two-sided alpha level of significance of
0.05. Error bars represent one standard deviation of the mean.
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from hyperplastic polyps (HP) to sessile serrated adenomas (SSA)[114,115]. The molecular
features of the HPs vary with respect to their colonic location. For example, HPs and SSAs
occurring in the proximal colon tend to have a higher frequency of BRAF mutations,
microsatellite instability (MSI) and CpG island methylator phenotype (CIMP) in comparison to
similar hyperplastic lesions found in the distal colon[17,116]. In addition, these lesions generally
lack APC mutations [9].

We believe that a subset of ACF described in the present study may represent precursor
lesions to this alternative pathway. We show that mutations to either KRAS or BRAF are
associated with the development of early hyperplasia within the distal colon. Consistent with the
molecular aberrations that accompany this alternative pathway [17], we have also identified MSI
and hypermethylation of Ras-association domain family 1a (RASSF1a) in 24% of hyperplastic
ACF [70]. Because of their limiting sample size, however, it has not been technically feasible to
combine genetic and proteomic analyses within the same specimen.

The novel methods

described in this report have begun to establish a robust approach that minimizes the amount of
sample required per assay (Figure 8), thus directly increasing the informative potential of a
single biopsy specimen. By using this technique, it may ultimately be possible to understand the
biological outcome of these early colonic lesions.

The equivalent distribution of KRAS and BRAF mutations within the serrated ACF
observed in the present study, where we have greatly increased our sample size, differs
somewhat from our previous findings [60]. While KRAS mutations occur at a greater frequency
in serrated ACF than previously reported (41.9 vs. 18.8%), we have confirmed the rare
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occurrence of BRAF mutations in hyperplastic-distended crypts [60]. Although we still cannot
determine with certainty whether these lesions occur in sequence or represent parallel pathways,
the similar frequency of BRAF and KRAS mutations in serrated ACF and the infrequent
occurrence of BRAF mutations in distended ACF raises the interesting possibility that distended
lesions precede serrated ones. It is possible that the acquisition of a BRAF mutation favors its
rapid growth into a serrated histological phenotype. On the other hand, KRAS-mutated distended
crypts may activate several key inhibitory pathways, such as RASSF1/2, that may impede their
progression to the serrated phenotype [117]. This mechanism may be bypassed in the event of a
BRAF mutation [117].

Understanding the downstream signaling consequences of these

oncogenic mutations will shed new insights into the relationship between serrated and distended
ACF and their potential role within the alternative pathway to carcinogenesis.

Using our NIA approach, we have been able for the first time to evaluate the extent of
ERK activation in biopsy specimens obtained from the human colon. Our results show that both
KRAS and BRAF mutations result in elevated levels of the activated, dually-phosphorylated
ERK2 isoform (Figure 11). Interestingly, ACF that are wild-type for BRAF and KRAS also
demonstrate ERK2 activation, suggesting that other mechanisms can stimulate this proliferative
pathway, possibly including members of the EGFR family or other mutations within the RasRaf-Mek pathway that have not yet been uncovered. A relatively high frequency of ErbB2/3 and
NRAS mutations in human CRC were recently described; their status in ACF, however, has not
been established[118]. Nevertheless, our results demonstrate the importance of ERK2 activation
in stimulating mucosal hyperplasia, especially since directly adjacent normal crypts do not
appear to have increased ERK activation (Figure 10 & 11). The high level of ERK2 activation
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compared to ERK1 is not surprising, given its known role in mediating cell proliferation and its
typically higher level of expression[119,120]. Interestingly, only WT and KRAS-mutant ACF
showed a significant activation of ERK1, while BRAF-positive ACF demonstrated only a modest
(< 2-fold) increase. It has been suggested that activated ERK1 may actually act as a competitive
inhibitor of ERK2, thereby blocking its activity[120,121]. These functional distinctions among
the ERK isoforms and their differential activation in ACF of varying histologies again support
the idea that the formation of distended crypts may precede the appearance of serrated ACF. Of
course, determining the activation status of the ERK isoforms within these very small epithelial
lesions would not have been possible using conventional immunohistochemistry, and further
underscores the advantages of this novel experimental approach.

An additional consideration is the potential role of oncogene-induced senescence in
determining the biological outcome of ACF.

Several recent mouse genetic studies have

examined the effects of these early oncogenic alterations within the intestinal mucosa. Carragher
et. al[122] showed that LSL-BRAFV600E x AhcreERT+/o mice with an activating mutation of the
BRAF oncogene develop serrated hyperplasia within three days after tamoxifen activation of the
Cre recombinase. The mice developed small intestinal tumors by twelve weeks following BRAF
activation, but this only occurred with a concurrent inactivation of p16INK4a via promoter
methylation. Similarly, Bennecke et. al[123] showed that LSL-KRASG12D x villin-Cre mice
develop serrated, hyperplastic colon crypts accompanied by increased p16INK4a expression. After
crossing these mice with Ink4a/Arf-/- mice, which are deficient for p16 expression, > 50% of
these mice developed tumors resembling traditional serrated adenomas by twelve weeks of age.
These studies in mice highlight the important role of p16-mediated senescence in reducing the
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transformative potential of these oncogenic mutations[124].

In the present study using IF

analysis, although p16 was consistently expressed within the colonic mucosa, its levels were not
significantly different between hyperplastic and normal crypts (Figure 12). However, it is
possible that the activation state of p16 is differentially affected by BRAF or KRAS mutations. It
has been shown that p16 is phosphorylated at four different serine residues, two of which may
have

different

effects

on

its

activation

state;

i.e.)

Ser8

(inactivating)[125]

and

Ser152(activating)[126]. In future studies, it may be possible to develop NIA-based assays to
examine these post-translational modifications of p16 to overcome the inherent limitations of IF
analysis.
In summary, we describe a new methodology that will increase the informative potential
of extremely small human biopsy specimens. By combining precise tissue microdissection of
early hyperplastic lesions with subsequent proteomic analysis, it is now possible to examine
post-translational modifications to specific signaling proteins within the context of underlying
genetic and histological changes. The results highlight the advantages of this approach over
conventional immunohistological methods by focusing on two ERK isoforms and their relative
activation states. Combining UV/IR microdissection with the NIA assay has made it possible to
obtain quantitative proteomic information within the context of histological changes and
upstream genetic abnormalities.
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Figure 12. p16 expression in normal colonic mucosa and KRAS and BRAF mutant ACF.
Expression of senescenc-associated p16 expression measured by immunofluorescence of frozen
tissue sections. Mutant ACF show positive nuclear staining of p16, while less nuclei show
positive staining in normal colonic mucosa (pink, example areas indicated by arrows). However,
this staining is variable across the study and difficult to quantify, therefore no conclusions can be
made at this time. Blue = DAPI nuclear stain(1:10,000); Green = 1° mouse mAb anti-human βcatenin for membrane visualization (Sigma, 1:2,000), 2° Alexa 488 goat anti-mouse IgG
(Invitrogen, 1:200). Red = 1° rabbit pAb anti-human p16 (Epitomics, 1:200), 2° Alexa 568 goat
anti-rabbit IgG (Invitrogen, 1:200). Rabbit IgG Isotype control shows no positive staining
(pictures not shown).
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CHAPTER 4

A DNA MASS SPECTROMETRY-BASED HIGH-THROUGHPUT METHOD
TO GENOTYPE HUMAN MICRODISSECTED ABERRANT CRYPT FOCI3
4.1 Introduction
Screening colonoscopy has been established as an effective strategy to reduce the risk of
colorectal cancer [127]. However, recent evidence suggests that protection may be most
successful in the distal colorectum since the incidence of proximal colon cancer has not been
significantly reduced by the implementation of widespread screening colonoscopy [128]. The
frequency of interval colon cancers, or those cancers developing between screening procedures,
raises the possibility that proximal tumors in particular may have accelerated growth
characteristics that limits the effectiveness of colonoscopy [129]. This lack of protection afforded
by colonoscopy, in particular within the proximal colon, underscores the need for advanced
endoscopic techniques that may be used to identify small precursor lesions that would otherwise
be missed by traditional screening approaches.

The following study was undertaken to more accurately define the molecular alterations
that are present within colonic ACF. Using DNA mass spectrometry (DNA-MS) combined with

3

The majority of this work has been previously published in Molecular Cancer Research (vol. 12; issue
6; pages 823-829) in June 2014 with the title “HD Chromoendoscopy Coupled with DNA Mass
Spectrometry Profiling Identifies Somatic Mutations in Microdissected Human Proximal Aberrant Crypt
Foci" (PMID:24651453)
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laser capture microdissection (LCM), we report a highly sensitive method to interrogate the
mutational spectrum of microscopic biopsies following their removal from the human colon. A
limited number of somatic mutations have been identified, including mutations to APCR876* and
FLT3I836M, as well as an insertion/deletion within the EGFR gene, underscoring the biological
significance of ACF within the context of CRC and in particular within the proximal colon.

4.2 Materials and Methods
4.2.1. Subject Selection
All subjects underwent a total screening colonoscopy at the University of Connecticut
Health Center (UCHC) in accordance with Institutional policies. Patients who met the
Amsterdam criteria for familial adenomatous polyposis (FAP) or hereditary non-polyposis CRC
(HNPCC) were excluded from the study. This study was performed only following Institutional
Review Board approval and receipt of written informed consent from the subjects.

4.2.2. ACF Collection and Characterization
ACF were identified in situ and biopsied from grossly normal-appearing colonic mucosa
during high-definition, close-focus magnifying chromoendsocopy. The proximal colon from the
cecum to the right hepatic flexure, in addition to the distal 20-cm of the colorectum, were
sprayed with a freshly prepared solution of 1% indigo carmine. ACF were visualized and
photographed using a close-focus colonoscope (Olympus, PCF-H190L; Olympus Corp., Center
Valley, PA) with visualization from 2-100 mm at 60x magnification. A finding was accepted as
an ACF if 5 or more crypts have an increased lumen diameter (1.5-2x), thick crypt walls, or
abnormally shaped lumens relative to the surrounding mucosa. In addition, the lesion must be
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less than 5 mm in diameter to be considered an ACF. Biopsies were immediately embedded in
freezing medium (OCT), flash-frozen, and stored at -80°C [130].

Frozen sections were stained with hematoxylin and eosin (H&E) and routine histological
analyses were performed by two independent, board-certified human gastrointestinal pathologists
blinded to clinical findings according to our previously established criteria (11). Dysplastic ACF
are characterized histologically by enlarged upper cryptal regions of irregular shape with
stratified, elongated nuclei and a general dysplastic appearance. Hyperplastic ACF are
characterized according to the same criteria applied to hyperplastic polyps[112]. These
hyperplastic ACF are sub-classified into serrated and distended (non-serrated) pathologies as
previously described [130]. Briefly, serrated ACF are defined as ACF that show stellate luminal
shape upon cross-section with a prominent component of columnar crypts with microvessicular
cytoplasm. Distended ACF lack serration, prominently feature goblet cells, and frequently
exhibit tufting of the surface epithelium.

4.2.2. Laser capture microdissection and DNA purification
A Veritas microdissector was used to capture ~5,000 cells (or the equivalent of
approximately one mm2 of collected tissue area) from 12-µm thick frozen serial sections of ACF
prepared on PEN membrane glass slides (Applied Biosystems, Foster City, CA). Genomic DNA
was extracted from aberrant crypts (isolated from surrounding stroma and normal mucosa by
LCM) using the PicoPure DNA extraction kit (Applied Biosystems). Samples were then cleaned
using the DNA Wizard protocol (Promega, Madison, WI)
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4.2.3. Somatic mutation screening using DNA mass-spectrometry
Mutation screening was performed at the Yale Center for Genome Analysis using the
Sequenom MASSArray DNA-MS approach. This method uses a matrix assisted laser desorption
ionization-time of flight mass spectrometry (MALDI-TOF MS) platform to detect single base
mutations with increased sensitivity[131]. Extracted DNA was amplified using multiplexed
OncoCarta PCR primers targeting 105 mutations across 22 known tumor suppressor and protooncogenes (v.3.0, Sequenom Inc., San Diego, CA; Table 12). The DNA concentration per
reaction approached 1 ng of gDNA, a concentration that is within the limits of detection for the
Sequenom platform[131]. DNA mass-spectrometry was carried out as previously described
[131]. Briefly, target regions are amplified through multiplex PCR reactions. Shrimp alkaline
phosphatase is added to the reaction to dephosphorylate unincorporated dNTPs and an extension
reaction mix is added. A post-PCR primer extension reaction creates a single nucleotide
extension using mass-modified terminators and the reactions are desalted using 6 mg of CLEAN
Resin. Reaction products are then printed onto a SpectroCHIP to be read by MALDI-TOF MS.
Mass spectrometry data is then analyzed using Typer4.0 software to identify sample genotype
with respect to the assayed mutation.

Somatic mutations were confirmed by extracting DNA from whole blood using the
DNAeasy Blood and Tissue Kit standard protocol (Qiagen; Venlo, Netherlands) and sequenced
by GeneWiz, Inc. (South Plainfield, NJ). To determine mutation status in adenomas, DNA was
extracted from two 10-micron FFPE curls using the QIAamp DNA FFPE Tissue Kit standard
protocol and sequenced (GeneWiz, Inc.) Primer sequences for PCR amplification and Sanger
sequencing were: EGFR F: 5’-CCCCAGCAATATCAGCCTTA-3’
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Table 12. Somatic mutations included in DNA-MS screen. 105 mutations to 22 known tumor
suppressors and proto-oncogenes were screened for each sample.
Gene

Mutations Screened

ABL1

M244V

APC

R876*, R1114*, E1309fs*4, Q1338*, Q1429*, S1465fs*3, T1661fs*9

BRAF

V471F, N581S, V600M

CDKN2A

R58*, E61*, E69*, H83Y, D84Y

CSF1R

L301S, Y969F/C/H/*

CTNNB1

A13T, V22A, W25-D32Del, S45A

EGFR

G719D, L730F, G735S, V742A, L747-P753>S, L747-T751>P, H773R, G810D/S, L858M

ERBB2

D769H, V777L

FLT3

D835Del, I836M

HRAS

G12C, G12R

JAK3

P132T, A572V, V722I

KRAS

Q22K

MET

T1010I, H1112R/Y, M1268T, Y1248C/H

MLH1

V384D

MYC

P57S, A59V, T731, N101T, A260A

PDGFRA

D842-D846>E/N, D846>G, D842-M844Del, D842-S847>EA, D842I/Y, R841-D842Del,
S566-E571>R

PTEN

K6fs*4, R130fs*4, R130G, R173C/H, R233*, P248fs*5, K267fs*9, V317fs*3, N323fs*2,
N323fs*21

RB1

E137*, L199*, R320*, R455*, R556*, R579*, L660fs*2, C706F, E784*

RET

A883F, C634R, D631-L633>E, D631G, D898-E901Del, E632-A640>VRP, E768D, F612C620Del

STK11

Q37*, Q170*, D194V, G196V, F264fs*22, P281fs*6, P281L, W332*

TP53

R306*

VHL

L85P, F148fs*11, L158Q, R161*, R167W
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R: 5’-ATGAGGTACTCGTCGGCATC-3’ ; APC F: 5’-GCATGCTCAAGAACCTCATTC-3’
R: 5’-TAGGTCGGCTGGGTATTGAC-3’ ; FLT3 F: 5’-AGAACTGCAGCCACCATAGC-3’ R:
5’-ACCTCATGATCTGCCCTCCT-3’ (Integrated DNA Technologies, Coralville, IA). Sanger
sequencing for BRAF and KRAS mutations was performed as previously described [60].

4.2.4. Immunohistochemistry
Immunohistochemistry (IHC) was performed on frozen ACF prepared at 7-µm thickness.
Sections were treated with 3% hydrogen peroxide, blocked and incubated in anti-β-catenin
primary antibody (1:2,000; Sigma-Aldrich Co, St. Louis, MO). Sections were incubated in
ImmPRESS anti-mouse Ig (Vector Laboratories, Burlingame, CA). Signal detection was
achieved using a 3,3’-diaminobenzidine solution (Vector Laboratories) and tissues were
counterstained with methyl green nuclear stain.

4.3 Results and Discussion

4.3.1. High-definition chromoendoscopy positively identifies ACF in the proximal colon
Using high-definition chromoendoscopy, we and others have previously demonstrated the
ability to identify ACF within the distal colon[72,73]. We have recently expanded our analysis to
include the identification of ACF within the proximal colon, a region of the colon that includes
the cecum to the splenic flexure (Figure 13A). A total of 96 patients have been screened and 88
proximal ACF and 1,010 distal ACF have been identified (Figure 13B). The majority of the
subjects were undergoing a screening colonoscopy (n=70/96; 73%) and approximately half of the
subjects (n = 47/96; 49%) had at least one polyp identified and removed during the procedure.
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Figure 13. Clinicopathological features of proximal ACF. A, High-definition magnifying
colonoscopy combined with dye-spray reveals diminutive flat lesions of the proximal
colorectum, including ACF and flat adenomas. B, Frequency of ACF according to colonic
location identified during screening chromoendoscopy. C, Histologic appearance of normal
colonic mucosa and ACF procured from the proximal colon. Proximal lesions display the same
type of morphologies commonly associated with distal colon ACF, including dysplasia and
hyperplasia (distended and serrated) (200x magnification; bar = 60 µm).
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Histologic evaluation reveals that proximal ACF harbor the full spectrum of established
histologic abnormalities present within distal ACF, including hyperplasia (serrated or distended)
and dysplasia (Figure 13C).

ACF within the distal colon share many genetic and histologic abnormalities associated
with more advanced colonic neoplasia. For example, hyperplastic ACF commonly harbor BRAF
or KRAS mutations[60], resulting in increased ERK activation[130]. The presence of ACF with
dysplastic histological features, however, is uncommon within the distal colon, although in one
case a dysplastic ACF was found to carry a novel somatic mutation to the APC gene[60]. A high
frequency of APC mutations has been reported previously in dysplastic ACF[67], but the
inclusion of patients with FAP disease in this study may have exaggerated the prevalence of APC
mutations. In an earlier study, we found that, a significant percentage of ACF (~ 40%) do not
harbor mutations to BRAF or KRAS[130]. Thus in the present study, a broader genetic screen was
undertaken to identify additional mutations that may contribute to early neoplastic changes in the
colon.

4.3.2. Application of DNA-MS for high-throughput genotyping of ACF
Comprehensive mutation profiling of early neoplasia may provide insight into future
colon cancer risk[118]. However, there are a number of technical challenges associated with the
application of high-throughput screening strategies to the analysis of small mucosal biopsy
specimens. In addition, the number of morphologically abnormal colonic crypts within an ACF
biopsy is limited, necessitating the use of LCM to enrich for subpopulations of aberrant and
normal-appearing colonocytes. Recent advances in DNA-MS technology using MALDI-TOF
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have provided a high-throughput, multiplexed approach to allow somatic mutational profiling
with as little as 1 ng of input genomic DNA[131]. To examine the feasibility of performing
DNA-MS analyses on micro-dissected ACF samples, DNA was extracted from approximately
5,000 colonocytes and subjected to the MASSArray PCR standard protocol. Amplification of
genomic loci was achieved with less than 1 ng of input genomic DNA (Figure 14). A total of
twenty-six micro-dissected ACF were then subjected to DNA-MS analyses. This group included
seven proximal ACF, nineteen distal ACF, and four normal colon biopsies.

As shown in Figure 15A, a proximal, serrated hyperplastic ACF was positive for the inframe insertion/deletion, c.2239_2251delTTAAGAGAAGCAAinsC (AA:L747_T751>P) in the
EGFR gene (19.6% deletion: 80.4% wild-type) as detected by MASSArray This mutation was
not present in the subject's blood, confirming that it was somatically acquired While EGFR
mutations occur in approximately 6% of colorectal cancers (COSMIC, n = 3,102), they are much
more frequent in lung adenocarcinomas (25.2%, COSMIC, n = 26,293). This specific mutation
has not been previously detected in colorectal cancer and accounts for <1% of lung EGFR
mutations, but is associated with a gain of EGFR function [132].

Additionally, a distal, distended hyperplastic ACF was positive for a FLT3 c.2508C>G
(I836M) mutation (24.0% mutant: 76.0% wild-type) and confirmed by Sanger-sequencing to be
somatic (Figure 15B). FLT3 mutations have widely been implicated in cases of acute myeloid
leukemia (23.5%, COSMIC, n = 63,213) and mutations to FLT3 occur in 4.8% of colorectal
cancers (COSMIC, n = 1,003). To our knowledge, the c.2508C>G mutation found in this study
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Figure 14. Sequenom-based PCR amplification of LCM genomic DNA. Suitable
amplification of genomic loci from three microdissected ACF samples was accomplished using
the Sequenom standard PCR protocol. Microdissected ACF DNA achieved the equivalent
amplification levels obtained using 1 ng of input DNA. The loci amplified is a 462 nt region of
RRBP1 using the following primers: F (exon): 5’-AGATGGCGAAAACTCACCACC-3’ and R
(intron): 5’- GCCTTTTTGCCCTGAGTAGT-3’. The primers span an intron-exon border to
restrict amplification to the genomic DNA template.

85

Ctrl gDNA
Input genomic DNA (ng)

20

10

2

1

462 nt

86

ACF

Figure 15. DNA-MS identifies FLT3I836M and a deletion to EGFR gene in hyperplastic ACF.
A, DNA-MS identification of an insertion/deletion to the EGFR gene in a serrated hyperplastic
proximal colon ACF. B, DNA-MS detection of a G>C missense mutation resulting in FLT3I836M
somatic mutation in a distended hyperplastic distal colon ACF. UEP=unextended primer
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has never before been reported in colorectal cancer. The I836M missense mutation has been
shown previously to cause constitutive activation of the receptor tyrosine kinase and subsequent
downstream signaling[133]. Constitutive activation of these two receptor tyrosine kinases, not
previously implicated in ACF formation, may contribute to the aberrant activation of MAPK
signaling reported earlier in hyperplastic lesions[130].

While the commercially available panel used in this study does not include KRAS or
BRAF, we have previously reported a high frequency of mutations to these protooncogenes in
distal hyperplastic ACF using conventional PCR-based sequencing [60,130]. Thus to establish
the presence of BRAFV600E and KRAS (codons 12 and 13) mutations, Sanger-sequencing was
performed on seven randomly selected ACF that had no other somatic mutations detected by the
OncoCarta panel. Four of the seven ACF were positive for KRAS mutations and none of the ACF
had BRAFV600E mutations.

4.3.3. DNA mass spectrometry identifies a rare somatic APC mutation in a proximal colon
ACF
An APCR876* mutation, a c.2626C>T (30.4% mutant T: 69.6% wild-type C), was
identified in a proximal dysplastic ACF (Figure 16A) In order to determine the function of this
rare mutation, immunolocalization of the Wnt target protein, β-catenin, was performed on the
dysplastic ACF. As shown in Figure 16B, there was an increase in nuclear accumulation of βcatenin in the dysplastic colonocytes compared to adjacent normal crypts. While mutations to
APC are frequently detected in colorectal cancers (42%; COSMIC, n=3,982), the APCR876*
mutation is relatively rare, accounting for approximately 2.5% of all APC mutations. The
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Figure 16. DNA-MS reveals APCR876* somatic mutation in a proximal dysplastic ACF. A,
DNA-MS reveals a c.2626C>T substitution resulting in an APCR876* mutation in a proximal
dysplastic ACF. UEP = unextended primer. B, IHC demonstrates an accumulation of nuclear βcatenin (black arrowheads) in dysplastic crypts positive for the APCR876* mutation compared to
adjacent normal crypts. (400x magnification; bar = 30 µm) C, Sanger sequencing confirms that
the APCR876* mutation is somatically acquired. Blood and synchronous tubular adenomas are
wild-type at codon 876 of APC.
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c.2626C>T non-sense mutation is most commonly somatically acquired[134], although it has
occasionally been detected in FAP pedigrees [134-136]. In the present study, however, this
mutation was confirmed to be somatic, as it was not detected in a matched blood sample (Figure
16C), thereby ruling out the possibility of underlying FAP disease. Interestingly, this mutation
was not detected in any of the three synchronous tubular adenomas removed during the
chromoendoscopy procedure (Figure 16C).

Sporadic forms of CRC are most likely the result of early somatic mutations resulting in
the clonal expansion of initiated progenitor cells. ACF have been shown to be monoclonal and as
such are likely the direct consequence of this initial clonal expansion [137]. Polyps and
adenomas are presumed to arise from these lesions following the accumulation of multiple
genetic alterations within this initiated cell population. Clearly, additional somatic mutations
must occur to drive neoplastic progression [113]. Additional changes have been identified in
early stages of CRC that contribute to carcinogenesis, including the acquisition of aberrant
promoter methylation [72] and microsatellite instability [70]. Therefore, it is reasonable to
anticipate that only a small percentage of ACF may sustain multiple oncogenic mutations at this
early precancerous stage. In fact, in the present study there was no evidence for the presence of
multiple somatic mutations, at least within the cancer panel that was tested.

The in situ identification of colonic ACF, and in particular those from the proximal colon,
is dependent upon the use of dye-spray and high-definition magnifying endoscopy and we
believe that in some cases this additional clinical effort is warranted. For example, the
identification of the APC mutation, APCR876*, associated with the formation of aggressive,
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invasive carcinomas[138], in a commonly missed mucosal lesion underscores the potential
preventive benefit of implementing this clinical approach to larger patient populations. It is
possible that ACF that harbor this and other significant somatic mutations have the capacity to
rapidly progress to a more advanced neoplasia, perhaps representing a subset of “missed lesions”
that may be responsible for interval colon cancers. Expanded molecular classification of
proximal ACF with a DNA-MS panel designed specifically for CRC, as well as establishing
detailed associations of proximal ACF with known CRC risk factors, as explored in the next
chapter, will be necessary to firmly establish their pre-malignant potential and utility as a
surrogate marker for future cancer risk.
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CHAPTER 5

PROXIMAL ABERRANT CRYPT FOCI AS A MARKER OF COLONIC
MUCOSA AT RISK

5.1 Introduction
In the following study, we describe the routine study of ACF in both the proximal
(including the cecum, ascending colon and hepatic flexure) and distal colorectum (distal 20-cm
of the sigmoid colon, including the rectum) in a large screening population over a two-year
period. We utilized high-definition chromoendoscopy to characterize these ACF for their
clinicopathologic and molecular features. To do this we developed a custom high-throughput
DNA mass spectrometry (DNA-MS) panel with coverage of 112 mutation targets in 12 CRCrelated tumor suppressors and proto-oncogenes. In addition, detailed demographic information
was collected on these patients and statistical models were used to associated proximal ACF with
known CRC risk factors. This study is a direct follow-up to pilot study presented in Chapter 4.
We demonstrate here that proximal ACF, in particular, may represent missed lesions that
contribute to interval CRC and as such act as an important marker of ‘at-risk’ colonic mucosa.

5.2 Materials and Methods
5.2.1. Subject selection
168 patients underwent total colonoscopy at the University of Connecticut Health Center
in accordance with Institutional policies. Patients were excluded from the study if they had
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previously undergone screening or surveillance colonoscopy at another Institution or were
suspected to have an inherited CRC genetic disorder such as familial adenomatous polyposis
(FAP) or hereditary non-polyposis colon cancer (HNPCC). The study was performed after
receiving approval from an Institutional Review Board, and all subjects provided written
informed consent prior to all procedures.

5.2.2. ACF collection and characterization
ACF were isolated from grossly normal-appearing colonic mucosa as previously
described[75]. Briefly, the proximal (the cecum and ascending colon, including the hepatic
flexure) and distal 20-cm of the colorectum were sprayed with 1% indigo carmine solution
administered through a spray catheter. ACF were visualized and photographed using Olympus
high-definition endoscopes (PCX-190, Olympus Corp., Center Valley, PA) capable of 60x
magnification with a focal length of 2 to 100 mm. Up to ten ACF per subject were biopsied using
forceps and colonic location, diameter and endoscopic appearance were recorded. Normal biopsy
specimens, one each from both the proximal and distal colon, were routinely collected. Biopsy
specimens were immediately embedded in OCT, flash frozen and stored at -80°C.

A systematic pathologic analysis of ACF and normal biopsies was performed by a human
gastrointestinal (GI) pathologist (T.V.R) blinded to endoscopic findings and a skilled technician,
as previously described[75]. A subset of ACF (n=96) was analyzed by a second human GI
pathologist (M.J.O’B) with good inter-rater agreement across the four possible pathologies
(77.1% agreement, Kappa = 0.689 [S.E.=0.055; 95% CI: 0.58 – 0.80]). Blinded biopsies were
confirmed to be either dysplastic or hyperplastic ACF or normal mucosa. Hyperplastic ACF were
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further sub-classified into serrated and non-serrated (distended) pathologies. Biopsy specimens
with the presence of ‘pseudo’ hyperplasia or dysplasia-like pathologic appearance due to the
presence of a lymphoid follicle are not representative of a classic ACF and were considered
“false-positive” [59,139].. ACF biopsy specimens that showed no histologic evidence of
hyperplasia or dysplasia were considered a ‘missed biopsy’ and also not counted.

5.2.3 Laser capture microdissection and DNA purification
Frozen serial sections of colon biopsies were prepared on Arcturus PEN membrane glass
slides (Applied Biosystems, Foster City, CA). Slides were dehydrated with ethanol and xylenes
and LCM was performed using a Veritas microdissection instrument (Applied Biosystems).
Morphologically distinct aberrant crypt populations, consisting of approximately 3-5,000 cells
(the equivalent of 1 mm2 of collected tissue area), were isolated on CapSure Macro LCM caps
(Applied Biosystems) from adjacent normal mucosa and the surrounding stroma. Adjacent
normal mucosa was separately collected when available. Genomic DNA was extracted on cap
according to the PicoPure DNA extraction kit (Applied Biosystems) and cleaned using the DNA
Wizard (Promega, Madison, WI) standard protocols.

5.2.4. DNA-MS mutation profiling
DNA-MS profiling was performed at the Yale Center for Genome Analysis on the
MASSArray platform (Sequenom, Inc., San Diego, CA). The MASSArray platform uses matrixassisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry to detect
single base mutations with increased sensitivity as previously described (Drew MCR 2014). A
custom panel of 112 mutations to 12 known CRC-related tumor suppressors and proto96

oncogenes was created using pilot study data[75], COSMIC and TCGA database mutation
frequencies.

5.2.5. MSI analysis
MSI analysis was performed using five mononucleotide repeat microsatellite targets
(BAT-25, BAT-26, NR-21, NR-24, and NR-27) in a pentaplex PCR assay. Primer sequences
have been previously described[18,19]; each primer pair was fluorescently labeled with one of
two markers: 6-FAM or NED. Pentaplex PCR was performed in a T100 Thermal Cycler (Biorad,
Hercules, CA) with 1 µL of purified DNA using a touchdown thermal cycling profile. The PCR
conditions consisted of an initial 10 minute denaturation step at 95°C, followed by 16 cycles at
95°C for 30 s, 60°C for 45 s (-0.5°C/cycle), 72°C for 30 s, followed by 34 cycles at 94°C for 30
s, 40°C for 45 s and 72°C for 30 s with a final extension at 72°C for 10 min. Amplified PCR
products were sent to Genewiz, Inc., where a fluorescent size standard (LIZ) was added and
samples were diluted 1:3 with formamide, and run on an Avant automated capillary
electrophoresis DNA sequencer (Applied Biosystems). Peaks were analyzed using the
PeakScanner Software v1.0 (Applied Biosystems). Samples that demonstrated no instability in
any loci were considered microsatellite stable (MSS), instability in one of five loci were
considered to have a microsatellite instability low phenotype (MSI-L), and instability in two or
more loci were considered to have a microsatellite instability high phenotype (MSI-H).

5.2.6. Statistical analysis
Standard t-test and Cochran-Mantel-Haenszel χ2 (CMH) tests were used for group
comparisons for numerical responses (e.g. age, BMI) and categorical responses (e.g. gender,
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smoking history, endoscopist), respectively. Negative binomial models were used to adjust for
known risk factors age, BMI, gender, and smoking history. Current and former smokers were
grouped together as “ever” smokers and compared to never smokers. To control for intraobserver variation, we also adjusted for endoscopist, as TJD (63% of all cases) vs. others (JCA
27%; BB 10%). Negative or Poisson binomial regression models are more appropriate for count
data like the data in this study rather than logistic or linear regression models. Due to the
presence of overdispersion (the variance is greater than the mean) in the data, use of the Poisson
model is inappropriate as the negative binomial model accounts for this overdispersion as a
variable in the model. All dispersion parameters from the models were significantly larger than
zero, validating the use of the negative binomial model. All analyses were conducted using
Statistical Analysis Systems v.9.4 (SAS 9.4).

5.3 Results
5.3.1. Baseline Characteristics of the Cohort
Between January 2011 and June 2013, a total of 168 subjects were enrolled and underwent the
ACF screening procedure. Table 13 presents descriptive statistics of the study population. These
subjects had a mean age of 56.4 ± 7.8 years and were primarily male (60.1%) and Caucasian
(80.3%). The majority of the subjects were never smokers (53.0%) and only 10.7% were current
smokers. The mean BMI was 29.5 and the subjects were stratified by the BMI categories normal
(<25.0; 23.8%), overweight (25.0 - <30; 39.9%), and obese (≥30; 36.3%). The majority of
subjects did not have a family history of CRC (69.1%) and were undergoing screening
colonoscopy (74.4%).
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Table 13. Characteristics of the Subjects with and without proximal ACF.

Total
(n =168)
56.4 ± 7.8

Subjects
No Proximal ACF
(n = 77)
54.9 ± 8.4

≥1 Prox. ACF
(n = 91)
57.6 ± 7.1

101 (60.1)
67 (39.9)

44 (43.6)
33 (49.2)

57 (56.4)
34 (50.8)

0.4700, CMH

18 (10.7)
61 (36.3)
89 (53.0)

8 (44.4)
25 (41.0)
44 (49.4)

10 (55.6)
36 (59.0)
45 (50.6)

0.3210, CMH

BMI, mean ± SD
Normal (<25.0), n (%)
Overweight (25.0-29.9), n (%)
Obese (≥30), n (%)

29.5 ± 6.1
40 (23.8)
67 (39.9)
61 (36.3)

29.1 ± 6.7
21 (52.5)
26 (38.8)
30 (49.2)

29.9 ± 5.6
19 (47.5)
41 (61.2)
31 (50.8)

0.4073, t-test

Family History of CRC, n (%)
No
Yes

116 (69.1)
52 (30.9)

55 (47.4)
22 (42.3)

61 (52.6)
30 (57.7)

0.5404, CMH

Procedure MD, n (%)
TJD
JCA
BB

105 (62.5)
46 (27.4)
17 (10.1)

45 (42.9)
22 (47.8)
10 (58.8)

60 (57.1)
24 (52.2)
7 (41.2)

0.3190, CMH

Race, n (%)
Caucasian
African American
Other

135 (80.3)
26 (15.5)
7 (4.2)

59 (43.7)
13 (50.0)
5 (71.4)

76 (56.3)
13 (50.0)
2 (28.6)

0.2639, CMH

Indication, n (%)
Screening
Surveillance

125 (74.4)
43 (25.6)

63 (50.4)
14 (32.6)

62 (49.6)
29 (67.4)

0.0434*, CMH

15.5 ± 14.6
0.9 ± 1.2
14.6 ± 14.3

11.4 ± 11.1
N/A
11.4 ± 11.1

18.9 ± 16.3
1.7 ± 1.2
17.2 ± 16.2

0.0006**, t-test

1.1 ± 1.5
77 (45.8)
91 (54.2)

0.7 ± 1.3
45 (58.4)
32 (35.2)

1.4 ± 1.6
32 (41.6)
59 (64.8)

0.0017**, t-test
0.0026**, CMH

Variable
Age, mean ± SD
Sex, n (%)
Male
Female
Smoker, n (%)
Current
Former
Never

No. of ACF, mean ± S.D.
Proximal ACF
Distal ACF
Synchronous Polyps, mean ± S.D.
No Polyps, n (%)
≥1 Polyps, n (%)

†Denotes Cochran-Mantel-Haenszel Statistic.
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P value

0.0245*, t-test
†

5.3.2. Proximal ACF are Rare and Predict the Occurrence of Synchronous Neoplasia
A total of 2,598 ACF were counted in the subjects’ proximal and distal colons with a
mean of 15.5 ACF/subject. Only 5.8% of these ACF were in the proximal colon (mean = 0.9
proximal ACF /subject), while distal ACF contribute greatly to this number (14.6 distal
ACF/patient; range) (Table 13). ACF multiplicity within the population was modeled using
negative binomial regression while adjusting for age, gender, smoking status, BMI, and
procedure MD (Table 14). Age (p=0.0026), smoking status (p=0.0269) and procedure MD
(0.0008), were all significantly associated with higher ACF counts.

Approximately 54% of the population (n=91) had at least one proximal ACF. The study
population was stratified according to those that had at least one proximal ACF and those that
only had distal ACF. Pair-wise comparisons were performed between the two groups. Subjects
with a proximal ACF were significantly older (mean = 57.6 years; t-test, p = 0.0245) and more
likely to be undergoing surveillance colonoscopy (Cochran-Mantel-Haenzel χ2, p = 0.0434) than
patients with no proximal ACF. Additionally, those harboring a proximal ACF have significantly
more ACF throughout their colon than those that do not (Figure 17A; p=0.0006, t-test). Distal
ACF numbers using negative binomial regression were modeled while adjusting for other
significant covariates in order to examine proximal ACF number as a predictor variable (Table
15). The model confirms that higher distal ACF counts are significantly associated with proximal
ACF number (p=0.0184).

100

Table 14. Negative binomial model of total ACF. (* = p<0.05; ** = p<0.01)
Variable
Estimate (95% CL)
S.E.
P value
(*)
Age
0.0263 (0.01, 0.04)
0.0089 0.0032
**
Gender (M)
0.0354 (-0.24, 0.31)
0.1392 0.7992
Smoker (Ever)
0.2929 (0.03, 0.55)
0.1328 0.0274
*
BMI
-0.0015 (-0.02, 0.02)
0.0108 0.8882
Procedure MD (TJD)
0.5018 (0.22, 0.78)
0.1424 0.0004
**
Intercept = 0.7659 (-0.43, 1.97), SE = 0.61, p=0.2110; Dispersion = 0.6396 (0.51, 0.81), SE = 0.08
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Figure 17. Proximal ACF incidence may indicate a field defect. A.) Total colon ACF counts
for subjects with and without proximal (prox) ACF. Subjects with at least one proximal ACF
have significantly higher (t-test; p<0.01) total colon ACF counts than those without ACF. B.)
Subjects with at least one proximal ACF are significantly more likely to harbor a synchronous
adenoma or polyp than those without proximal ACF (OR=2.59 [1.38-4.84]; Cochran-MantelHaenzel χ2, p = 0.003). C&D.)To adjust for other CRC risk-factors, negative binomial modeling
is used to predict the expected number of proximal ACF in a subject according to their (C) distal
ACF counts and (D) number of synchronous polyps. Other CRC risk factors were kept constant
at baseline or average value to generate predicted outcomes: age = 56; gender = male; smoking
history = never; BMI = 30; Procedure MD = TJD.
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This suggests that proximal ACF may indicate a possible field-defect within the colonic
mucosa. Therefore, we examined whether these lesions associated with a firmly established CRC
risk factor: the presence of one or more polyp or adenoma. The study population was further
stratified according to whether or not they had a synchronous adenoma or polyp. Subjects with a
proximal ACF are nearly three times as likely to have at least one synchronous polyp or adenoma
somewhere within their colon (Figure 17B; OR=2.59 [1.38-4.84]; Cochran-Mantel-Haenzel χ2,
p=0.003). Negative binomial models predicting proximal ACF were used to confirm these
findings, where separately, distal ACF number (Table 16) and synchronous polyp counts (Table
17) were included as predictor variables in addition to the covariates of age, gender, smoking
status, indication, and procedure MD. Both distal ACF (p=0.018) and synchronous polyps
(p=0.014) are strongly associated with proximal ACF. Expected proximal ACF counts were
determined according to distal ACF count (Figure 17C) and the number of synchronous
neoplasia (Figure 17D). Subjects are likely to have at least one proximal ACF if they have five
or more distal ACF or at least one polyp, assuming they are at baseline or average risk for the
other risk factors included in the model.

5.3.3. Proximal ACF are frequently dysplastic
A total of 760 ACF biopsies were subjected to routine pathologic assessment for histologic
characteristics of ACF. The frequency of ACF pathologies by location is presented in Table 18.
Of these biopsy specimens, 518 were confirmed to have an underlying ACF pathology (68.2%,
positive hit-rate). False positives (e.g. the presence of a lymphoid follicle), contributed slightly
more (19.2%) than missed biopsies (12.6%) to the negative hit rate. Additionally, there is no
significant difference in these rates between colonic locations.
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Table 15. Negative binomial model of distal ACF. (* = p<0.05; ** = p<0.01)
Variable
Estimate (95% CL)
S.E.
P value
(*)
Age
0.0247 (0.01, 0.04)
0.0091 0.0068
**
Gender (M)
-0.0194 (-0.30, 0.27)
0.1453 0.8935
Smoker (Ever)
0.3676 (0.09, 0.64)
0.1396 0.0084
**
BMI
-0.0003 (-0.02, 0.02)
0.0111 0.9783
Procedure MD (TJD)
0.4287 (0.13, 0.72)
0.1424 0.0044
**
Proximal ACF Number
0.1393 (0.02, 0.25)
0.0591 0.0184
*
Intercept = 0.6603 (-0.57, 1.89), SE = 0.63, p=0.2926; Dispersion = 0.6834 (0.54, 0.86), SE = 0.08
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Table 16. Negative binomial model of proximal ACF with distal ACF as a predictor variable. (*
= p<0.05; ** = p<0.01)
Variable
Estimate (95% CL)
S.E.
P value
(*)
Age
0.0018 (-0.02, 0.03)
0.0134 0.8930
Gender (M)
0.3338 (-0.07, 0.74)
0.2060 0.1052
Smoker (Ever)
-0.1780 (-0.57, 0.21)
0.1986 0.3701
BMI
0.0068 (-0.03, 0.03)
0.0164 0.6763
Procedure MD (TJD)
0.2604 (-0.17, 0.69)
0.2215 0.2398
Distal ACF Number
0.0156 (0.003, 0.03)
0.0064 0.0141
*
Intercept = -0.9673 (-2.74, 0.81), SE = 0.63, p=0.2926; Dispersion = 0.4084 (0.18, 0.94), SE = 0.17
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Table 17. Negative binomial model of proximal ACF with synchronous polyps as a predictor
variable. (* = p<0.05; ** = p<0.01)
Variable
Estimate (95% CL)
S.E.
P value
(*)
Age
0.0084 (-0.02, 0.03)
0.0130 0.5163
Gender (M)
0.1642 (-0.25, 0.27)
0.2090 0.4323
Smoker (Ever)
-0.1417 (-0.52, 0.24)
0.1951 0.4676
BMI
-0.0004 (-0.03, 0.03)
0.0164 0.9828
Procedure MD (TJD)
0.3507 (-0.07, 0.77)
0.2142 0.1015
Total Polyp Number
0.1771 (0.06, 0.29)
0.0589 0.0026
***
Intercept = -1.0752 (-2.84, 0.69), SE = 0.90, p=0.2329; Dispersion = 0.3779 (0.16, 0.90), SE = 0.17
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Table 18. ACF pathologies by colonic location.

Pathology
†

Dysplastic
Hyperplastic
‡
Serrated
Non-serrated

Hit Rate*
False-Positive Rate

ACF Location
Proximal Colon
Distal Colon
(n = 91)
(n = 427)
†

52 (57.1 )

56 (13.1)

11 (12.1)
28 (30.8)

271 (63.5 )
100 (23.4)

66.9%
16.9%

68.4%
19.7%

‡

*False Positive rate and hit rate calculated from pathologic analysis performed on 760 biopsies
(136 proximal and 624 distal)
† OR[(proximal, distal) vs. (dysplastic, hyperplastic)] = 8.8 (95% CI: 5.4-14.6); χ2 p<0.0001
‡ OR[(proximal, distal) vs. (serrated, non-serrated)] = 6.9 (95% CI: 3.3-14.4); χ2 p<0.0001
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Sampled ACF are more frequently hyperplastic (79%) throughout the colon, rather than
dysplastic (Table 18). However, in context of colonic location, proximal ACF are frequently
dysplastic (57%) and rarely serrated (12%). This is the opposite case in the distal colorectum,
where the majority of ACF are serrated (64%) and dysplastic ACF are firmly the minority (13%).
Non-serrated hyperplastic ACF are slightly more frequent in the proximal colon (31%) than the
distal colorectum (23%).

Odds ratios were calculated for pathology and location. The odds of a dysplastic ACF
being proximally located are approximately nine times more likely than it occurring in the distal
colon or being hyperplastic (Table 18,†; OR=8.83 [95% CI: 5.35-14.58]; χ2, p<0.0001). Among
hyperplastic ACF, the serrated histology is approximately seven times more likely to occur in the
distal colon than the proximal colon compared to non-serrated ACF (Table 18,‡; OR=6.90 [95%
CI: 3.31-14.38, χ2, p<0.0001).

5.3.4. Dysplastic ACF frequently have APC mutations, while hyperplastic ACF associate with
MAPK activating mutations.
We have previously demonstrated the ability to use DNA mass spectrometry to reliably
detect somatic mutations in microdissected ACF samples[75]. A custom mutation panel for
CRC-specific tumor suppressors and proto-oncogenes was developed (Table 19). Genomic DNA
was extracted from 42 microdissected proximal ACF, and 6 microdissected normal samples and
subjected to DNA-MS analyses. HAPMAP genomic DNA was used as a negative control. Forty
percent of the proximal ACF assayed were positive for a mutation covered by the panel.
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Table 19. Mutations screened for using the custom ACF DNA-MS panel.
Gene
(# mutations)

APC (11)
BRAF (5)
CDKN2A (7)
EGFR (15)
ERBB2 (8)
FLT3 (2)
HRAS (5)
KRAS (11)
MET (5)
NRAS (19)
PIK3CA (14)
TP53 (9)

Mutation Screened
E1306*, E1379*, N1661*, Q1338*, Q1367*, Q1378*, Q1429*, R1114*, R1450*,
R876*, S1465*
D594G, V600E/G/L/M
D84Y, E61*, E69*, E88*, H83Y, R58*, R80*
G719SC, L858R, L861Q, E746delGGA, E746delAAT, E746delATT,
L747delTTA, L747delTAA, S752IF, A750P, T751I, P753Q, T751PAS, R108K,
T790M
A775_G776insYVMA,
D769H,
G776SLC,
G776VC,
L755P,
P780_Y781insGSP, S779_P780insVGS, V777L
D835del, D835HY
G12VD, G13CRA, Q61H/K/LRP
A59T, G12A/C/D/R/S/V, G13V/D, Q61H/LRP
M1268T, R988C, T1010I, Y1248C, Y1253D
A18T, G12V/A/D/C/R/S, G13V/A/D/C/R/S, Q61E/K/L/R/P/H
C420R, C901F, E542K, E545K, H1047R/L/Y, H701P, M1043I, N345K, P539R,
Q546K, R38H, R88Q
D281G/Y/H, G245SRC, G248GW, R273C/H/L, V143A
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Positive mutation calls appear in Table 20. APC mutations were most frequent (14.3%)
followed by mutations to KRAS (11.9%) and BRAF (7.1%), respectively and these mutations
associate with specific pathologies. APC mutations are exclusively observed in dysplastic ACF
(6 of 6) while mutations implicated in mitogen-activated protein kinase (MAPK) activation
(KRAS, BRAF, NRAS, ERBB2) are primarily observed in hyperplastic ACF (9 of 11). No ACF
were positive for more than one mutation.

Eight of 19 dysplastic ACF (42.1%) were positive for a mutation as detected by the
panel. Five of these ACF were positive for non-sense point mutations to APC, either APCR876*
(c.2626C>T; n=3) or APCR1450* (c.4348C>T; n=2). One ACF was positive for a deletion
frameshift (p.APCS1465fs*3) resulting in a premature stop codon downstream of Ser(1465).
Additionally, a dysplastic ACF was positive for a BRAFV600E (c.1799T>A) mutation and another
was positive for a KRASG12D (c.35G>A) mutation.

Of the 23 hyperplastic ACF (serrated, n=8; non-serrated, n=15) assayed, 39.1% were
positive for a MAPK-associated gene mutation. Four non-serrated hyperplastic ACF were
positive for mutations within codon 12 of KRAS, one with p.G12D and three with p.G12V
(c.35G>T) mutations. Two additional non-serrated hyperplastic ACF were positive for ERBB2
mutations; one was positive for a missense mutation p.G776S (c.2326G>A) and the other an
insertion, p.A775_G776insYVMA (c.2324_2325insATACGTGATGGC). Two serrated ACF were
positive for BRAFV600E mutations while a third was positive for a NRASG13D (c.38G>A) mutation.

111

Table 20. Mutations detected by DNA-MS panel in microdissected proximal ACF.
ACF ID #
077-1
149-2
152-1
230-1
237-1
240-1
076-1
121-1
229-1
115-1
150-1
122-1
151-1
121-4
225-2
230-3
026-1

Pathology
Dysplastic
Dysplastic
Dysplastic
Dysplastic
Dysplastic
Dysplastic
Serrated
Serrated
Dysplastic
Distended
Distended
Distended
Dysplastic
Distended
Distended
Distended
Serrated

Gene
APC
APC
APC
APC
APC
APC
BRAF
BRAF
BRAF
ERBB2
ERBB2
KRAS
KRAS
KRAS
KRAS
KRAS
NRAS
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Mutation
R876*
R876*
R876*
R1450*
R1450*
S1465fs*3
V600E
V600E
V600E
A775_G776insYVMA
G776S
G12D
G12D
G12V
G12V
G12V
G13D

5.3.5. MSI is significantly associated with hyperplastic ACF, but not a colonic location.
We analyzed 35 proximal ACF (19 hyperplastic ACF; 16 dysplastic ACF) and 92 distal
ACF (79 hyperplastic ACF; 13 dysplastic ACF) for MSI. Samples positive for instability in two
or more microsatellite markers were considered MSI-H (Figure 18A, bottom), in only a single
marker, MSI-L, and no markers, MSS (Figure 18A, top). Thirty percent of ACF were found to
be MSI-H, with the majority of the MSI-H lesions being hyperplastic (89%) and distal (82%)
(Figure 18B). For group comparisons MSS and MSI-L were grouped together as there are no
established clinical, survival or prognostic, differences between MSI-L and MSS CRC[140-142].
MSI-H is more than three times more likely to be associated with a hyperplastic pathology rather
than dysplasia (Figure 18C; OR [hyperplastic, MSI-H] = 3.32 [95%CI: 1.07-10.33]; χ2, p =
0.03). There is no significant difference between the rates of MSI-H in serrated versus nonserrated hyperplastic ACF (χ2, p = 0.43). There is also no difference between the rates of MSI
according to colonic location (χ2, p = 0.13).

5.4 Discussion
Since being first described nearly 30 years ago [58], ACF have been carefully examined
in human and murine colons as surrogate markers of colorectal cancer risk or as endpoints for
chemoprevention trials [80,82,88,143,144]. Classically and especially in chemoprevention trials,
studies of ACF have been focused on endoscopic counts of distal ACF. As a result,
gastroenterologist interrater variability has undoubtedly clouded their practicality in providing
individual risk assessment[84], leading some to question their utility as a surrogate marker and,
ultimately, their role in tumorigenesis [83,86,87].
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Figure 18. Microsatellite instability in microdissected ACF. A.) Top; Allele size, in base
pairs, frequency spectrum of five microsatellite markers (NR-27, NR-21, NR-24, BAT-25, BAT26) in a microsatellite stable (MSS) ACF sample. Bottom; Four of five microsatellite markers (all
but NR-24) show signs of instability in a microdissected ACF, as measured by a decrease in
allele size (arrows). Two or more instable microsatellite markers indicate high microsatellite
instability (MSI-H), as shown here, while instability measured in a single marker indicates low
instability (MSI-L). B.) Rates of MSS (white bars), MSI-L (grey bars), and MSI-H (black bars)
in microdissected ACF, grouped by colonic location and lesion pathology. C.) MSI-H
significantly associates with hyperplastic ACF (35% of all hyperplastic ACF; n=98) compared to
dysplastic ACF (14% of all dysplastic ACF; n=29); OR (hyperplastic, MSI-H) = 3.32 [95%CI:
1.07-10.33; (Fisher’s Exact test, p=0.037)].
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We demonstrate in this study that the procedure endoscopist does have a significant
effect on ACF counts even within the same clinical setting. However, after carefully adjusting
for this effect, there are still significant associations between ACF numbers and other CRC risk
factors such as age and smoking history (Tables 13 & 14), as previously described[145].
Furthermore, the high hit-rate and low false-positive rate demonstrates that an ACF’s endoscopic
appearance is a reliable measure of an underlying pathology (Table 18), not unlike the
endoscopic identification of polyps or adenomas.

The disproportionate incidence of ACF between regions of the colon may mean that the
presence of a proximal ACF may be a distinct surrogate marker of CRC. This is not intended to
imply that distal ACF are not important CRC biomarkers, as we have recently shown that
increased distal ACF counts significantly associate with increased risk of advanced neoplasia
upon five-year follow-up[74]; This study demonstrates that proximal ACF are associated with
other markers of CRC risk including the incidence of synchronous neoplasia as well as elevated
distal ACF counts (Figure 18). The presence of a proximal ACF may indicate a potential field
effect or a ‘fertile field’ for neoplastic initiation.

Additionally, the high rate of dysplasia in proximal ACF further implicates their
importance in CRC tumorigenesis and as a surrogate marker. Compared to the distal colon where
ACF are primarily hyperplastic, the discretionary line between a proximal ACF and a “microadenoma” may be much less clear[146,147], especially considering the frequency of significant
APC mutations. APCR876* and APCR1450* are non-sense mutations resulting in premature
truncations to the APC gene. Another dysplastic ACF was positive for a deletion frameshift
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(APCS1465fs*3). Both APCR1450* and this deletion occur in the gene region commonly referred to as
the “mutation cluster region” (region spanning base pairs 1263-1589) and have been detected in
colorectal cancers. These two mutations result in truncation of the APC protein and impaired
beta-catenin binding capacity [13]. The APCR876* mutation, while detected rarely in CRC, has
previously been detected in ACF and although located outside the mutation cluster region, results
in a truncated protein product and nuclear beta-catenin accumulation[75]. These ACF meet two
of the criteria of traditional (tubular/villous) adenomas: aberrant Wnt activation and cytological
dysplasia, and should be considered “pre-cancerous” lesions. Combined with the fact that
surveillance of these lesions is not routinely included as a part of screening endoscopy and its
possible that proximal ACF may significantly contribute to the incidence of interval CRC.

The high frequency of a detected mutation in proximal hyperplastic ACF suggests that a
subset of these lesions may be primed for CRC development as well. We previously
demonstrated (Chapter 3) the high frequency of KRAS (codons 12 and 13) and BRAFV600E
[60,76,148] mutations and the subsequent activation of the MAPK signaling cascade [130] in
distal hyperplastic ACF. The identification of additional drivers of MAPK signaling, a hallmark
of the serrated or alternative colon carcinogenesis pathway[4], such as ERBB2 and NRAS in
proximal hyperplastic ACF may have important implications in understanding serrated
carcinogenesis. To our knowledge this is the first description of these two genes being mutated in
human ACF, but not in CRC[118].

Importantly, MSI was significantly associated with hyperplastic ACF (Figure 18). MSI
has previously been determined to have an important role in colon carcinogenesis especially in
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cancers arising via the serrated pathway. The presence of MSI in ACF was first detected in
patients with concurrent CRC [68,69] and later in ACF endoscopic biopsy specimens[70].
Cancers arising from the proximal colon are associated with the serrated pathway and are more
likely to be microsatellite instable [4,149]. The association between hyperplastic ACF and MSI
was not found to be location dependent in the present study. However, considering the high
frequency of oncogenic mutation detected in these lesions and the increased risk for MSI, it is
apparent that a subset of these lesions may be at increased risk for neoplastic progression and
may warrant careful surveillance.
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CHAPTER 6

SUMMARY, CONCLUSIONS, & FUTURE DIRECTIONS
Screening colonoscopy and subsequent polypectomy has become the frontline CRC
prevention tool in the United States. However, modest CRC mortality and morbidity reduction
following its wide-spread implementation and the observation of interval cancers have
highlighted inherent limitations with routine or standard-of-care endoscopy. Routine lower
endoscopy consists of either sigmoidoscopy (endoscope only advances to, and not beyond, the
proximal sigmoid colon) or total colonoscopy (screened from cecum to anus) and has been
credited with a lowering of CRC risk in multiple studies [26-28]. However, endoscopy is
significantly more successful in preventing distal CRC compared to proximal CRC [25].
Needless to say, there are obvious reasons why sigmoidoscopy may be limited in preventing
proximal CRC; even though, numerous epidemiological studies have shown that compared to no
screening, sigmoidoscopy does reduce overall CRC risk [25]. Therefore, for the purposes of this
discussion, ‘colonoscopy’ or ‘endoscopy’ will be used interchangeably to refer to total
colonoscopy.

There are a few possible, non-mutually exclusive, explanations for the observed preventative
differences between colonic locations.
1. Cancers arising in the proximal colon may acquire an aggressive molecular phenotype
causing their rapid progression from precancerous lesions to malignancy; or,
2. Precancerous lesions within the proximal colon are difficult to detect or completely resect
using routine endoscopy.
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The traditional adenoma-carcinoma sequence provides a paradigm for explaining the
success of colonoscopy. The step-wise accumulation of molecular aberrations described takes
considerable time, years or even a decade, between the first initiating mutation and malignant
transformation[2]. Cells maintain many mechanisms to respond to stressors, such as oncogene
activation or DNA damage. Under normal conditions these cells will undergo senescence,
quiescence or apoptosis, to prevent the propagation of damaged and potentially harmful cells.
Therefore, for an initiated, precancerous cell to ultimately form a cancer, many of these
protective mechanisms must be bypassed either through epigenetic silencing of the genes
responsible or loss of function of the genes through mutation or chromosomal loss[150,151].
This explains why CRC cancers, but not precancerous polyps or adenomas, are typically
negative for the expression of potent tumor suppressors such as p16 or p53 [3,124].

Oncogene induced senescence (OIS) is a phenomenon that has been described in cell and
animal models of oncogene activation[124,152]. In response to oncogene activation, especially
KRAS and BRAF mutations, tumor suppressors such as p16 are upregulated and cells enter a
reversible, senescent state[122,123]. This effect has been observed in mouse models of RAS and
RAF activation{Bennecke, 2010 #441;Carragher, 2010 #180}. OIS may partially explain the
difference between proximal and distal ACF multiplicity. We hypothesize that distal ACF, which
we report are primarily hyperplastic, frequently carry BRAF and KRAS mutations and
significantly upregulate MAPK (Chapter 3), possess the appropriate characteristics to activate
OIS.

Initial

attempts

at

quantifying

p16

expression

in

ACF

using

conventional

immunofluorescence proved difficult. While p16 expression was apparent, the changes between
senescence-associated p16 expression and regular expression may be too slight to measure with
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immunohistology.

Additional studies, designed to sensitively measure RNA or protein

expression of OIS pathway components should be performed to further implicate the role of OIS
in ACF.

However, subsets of precancerous lesions may acquire molecular phenotypes that
accelerate tumorigenesis and bypass protective mechanisms. Inherited defects in MMR genes are
responsible for the CRC syndrome, HNPCC, in which 80% of all HNPCC patients will be
diagnosed with CRC[140]. Somatic acquisition of defects to MMR genes either through point
mutation or epigenetic silencing can cause a similar genomic instability phenotype, as measured
by MSI[17]. Cells lose their ability to recognize and repair DNA damage without intact MMR
function and may lose the ability to perpetuate pro-apoptotic signals[153].

Therefore, MSI-H

lesions may more readily bypass protective apoptotic responses and accumulate genetic
mutations at a significantly higher rate than MSS lesions. Importantly, MSI-H associates with
SPs, especially SSAs, which have a predilection for the proximal colon[4,37,46]. Moreover,
proximal CRCs are significantly more likely to be MSI-H than MSS[15,22].

We report here that 30% of ACF biopsy specimens were MSI-H consistent with early
acquisition of a genomic instability phenotype (Chapter 5). While the rate of MSI-H in ACF did
not significantly associate with a specific location in this study, MSI-H did specifically associate
with hyperplastic ACF, the putative precursors to SPs. We acknowledge that the study may have
been underpowered to measure site-specific associations of genomic instability (only 35
proximal ACF were available for MSI analysis). By increasing sample size, any relationship
between colonic location and MSI within ACF may become more apparent.
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Another proximally associated molecular phenotype of CRC is CIMP. While CIMP
status was not investigated by these studies, CIMP has previously been associated with proximal
cancers[17,22], SPs [15] and ACF[71]. Aberrant promoter methylation leading to loss of tumor
suppressor gene expression, may also contribute to a rapid transformation from early
precancerous lesion to malignancy [72]. Therefore it will be necessary to investigate epigenetic
features of ACF, especially in context of their colonic location in future experiments. Because
these are early lesions, to get an accurate representation of genome-wide epigenetic changes it
may be necessary to expand beyond the limited scope of established CIMP panels.

Advances in epigenomics have provided sensitive tools, such as reduced representation
bisulfite sequencing (RRBS)[154] or methylated CpG island recovery assay (MIRA)[155],
which can provide comprehensive DNA methylation analysis in frozen biopsy samples. By
doing so, insight may be obtained as to the earliest epigenetic changes resulting from or causing
CRC initiation. Focus could be placed on those genes and signaling pathways involved in OIS.
Proximal ACF, especially proximal hyperplastic ACF, may show early signs of the epigenetic
signatures of advanced neoplasia or CRC and may have distinctly different methylation patterns
compared to their distal or dysplastic counterparts.

These potential aggressive molecular phenotypes that may contribute to interval cancers
all have clear associations with SPs. As discussed in the introduction, SSAs are the most
accepted precancerous lesion of the serrated pathway and are very difficult to detect and resect
due to their sessile morphology, the presence of a mucous cap obscuring endoscopic detection,
and the lack of visually defined borders[12]. Furthermore, SSAs are likely to be proximally
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located. Prevention of serrated carcinomas by polypectomy may be less trivial than reducing
traditional carcinomas. Traditional adenomas are likely to be distally located and thus can be
detected by either total colonoscopy or sigmoidoscopy. Moreover, their typical pedunculation
and separation from the surrounding normal mucosa by a stalk-like projection may lead to easier
identification and more complete resection[8].

Considering these morphologic features, it is not difficult to envision why interval
cancers are more likely to be proximally located [31]. In fact, recent reports strongly implicate
that the majority, up to 75% of iCRCs are the direct result of missed lesions during index
colonoscopy[30-35]. While correlative, it appears the hardest to detect lesions and thus the most
likely to be missed lesions, are the most likely to harbor aggressive molecular phenotypes,
creating a potential perfect storm that may be responsible for interval cancers.

While gastroenterologists undoubtedly always perform careful endoscopic observation,
we present risk factors for polyp occurrence that may identify patients who would benefit from
the highest standard of care in an effort to reduce iCRC. Withdrawal time, for instance, is
correlated with a clinician’s adenoma detection rate[107] and thus inversely correlated with
iCRC incidence[30]. We confirm a number of known risk factors for polyp occurrence including
age, gender, and family history of CRC (Chapter 2). We also confirm the overall preventive
effect of aspirin. Interestingly, however, we demonstrate a subset of the population that may be
at increased risk for polyp occurrence: those that take aspirin daily and also have a history of
smoking. This finding extends the recent results of Ishikawa et al., who during a randomized
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clinical trial of aspirin and CRC recurrence found that smoking abrogated the protective effect of
aspirin and increased risk of CRC recurrence[105].

Once we stratified these results further according to polyp location and pathology, we
found that the protective effect of aspirin was limited to traditional adenomas. While we were
underpowered to study the interaction effect in the pathologic and location subtypes, smoking
was positively associated with serrated polyp occurrence. NSAIDs, including ibuprofen and
aspirin, have been shown to decrease total levels of cellular β-catenin and induce its
phosphorylation in addition to inhibiting other downstream signaling effects within the Wnt
pathway[57]. Since SPs are not associated with the canonical-Wnt signaling pathway, but instead
the MAPK signaling cascade it follows that they may not be prevented by regular aspirin use and
is consistent with our results. Therefore, a smoker who takes aspirin daily may not expect to be
as protected as a non-smoker because of their increased risk for SPs. However, a biological
explanation for the observed synergy between smoking and aspirin use leading to a higher risk of
polyps than those who smoke, but do not take aspirin, is not readily apparent. Further
investigation into this interaction is certainly warranted.

We also demonstrate that proximal lesions are significantly predicted by statin use and
family history compared to distal lesions; and separately, that SPs are predicted by smoking
status and BMI compared to traditional adenomas. Patients with these risk factors may be the
most likely to benefit from shortened surveillance intervals, increased withdrawal times or
advanced endoscopic techniques to increase the adenoma detection rate during index
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colonoscopy. Prospective clinical studies could be performed to measure the added benefit of
these different approaches in high-risk individuals.

Individuals who upon index colonoscopy had one or more precancerous lesion removed
are at greater risk for iCRC compared to the those with clean colonoscopies[31]. This suggests
that those patients with polyps upon index colonoscopy are likely to be harboring a precancerous
lesion that goes undetected during the initial colonoscopy. This is consistent with our results
showing that those patients in our study who were undergoing surveillance colonoscopy rather
than a screening colonoscopy were significantly more likely to have a traditional adenoma
somewhere within their colon (Chapter 2). It is possible that proximal ACF may represent the
missed lesion that is contributing to the high rate of adenomas and iCRC in this high-risk
population since ACF are routinely missed during standard endoscopy. Given the high frequency
of dysplasia within proximal ACF, the identification of somatic, loss-of-function APC mutations,
and their strong association with synchronous neoplasia, proximal ACF may be too important a
lesion to ignore in high-risk individuals (Chapters 4&5).

While the reliability of ACF endoscopic appearance has been questioned, the present
study demonstrates that the endoscopic appearance of an ACF is representative of an underlying,
but not specific, pathology. Within the proximal colon, where ACF multiplicity is much lower,
the frequency of dysplasia is considerably higher than previous studies that were limited to the
distal colon[83]. Furthermore, they correlate with synchronous neoplasia and higher distal ACF
counts, established markers of the colonic mucosa at risk. Therefore, proximal ACF may
represent a distinctly different surrogate marker from distal ACF counts.
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Additionally, the use of chromoendoscopic from the cecum to the hepatic flexure and
identification of ACF should be more feasible than attempting to make total colon ACF
screening a standard practice. By limiting ACF screening to the cecum and ascending colon, only
a few additional minutes (<10) will be added to the standard colonoscopy procedure. Also, this
measure may only be necessary in those individuals the clinician feels may be at risk for iCRC
development. The presence of an adenoma or polyp on the way to the cecum during total
colonoscopy could serve as an easily identifiable clinical indication for when this additional step
may be warranted.

The addition of dye-spray and close surveillance of the proximal colon may have
supplemental benefits for CRC prevention not specific to the identification and removal of
proximal ACF. During careful proximal ACF screening, withdrawal times will certainly be
extended thereby potentially increasing the adenoma detection rate. The use of dye-spray may
also help in the identification and resection of SSAs by providing clearer visualization of the
lesion and its borders; an observation that was made, but not specifically investigated, during the
course of the clinical study.

In summary, proximal ACF are rare compared to their distal counterparts, but may
signify the presence of a field defect or a colonic mucosa at higher risk for CRC development.
Additionally, the high frequency of dysplasia and APC mutations, specifically, in biopsied
proximal ACF, suggests that dye-spray and HD endoscopy may be warranted in certain cases, for
example those with at least one synchronous polyp, of advanced age, or with a history of
smoking. Given that proximal ACF are not included in routine screening, frequently possess
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clinicopathologic and molecular features observed in neoplasia, and associate with other known
CRC risk factors, it is clear that these lesions harbor some level of carcinogenic potential. As
such they may represent a significant “missed” lesion and directly contribute to interval cancers.
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APPENDIX
DETAILED PATHOLOGIC CHARACTERIZATION

We have used the following set of criteria for diagnosing polyps based on the recommendations
of the World Health Organization[7]:

Serration is the presence of in-foldings of the surface epithelium of the crypt, creating
micropapillations towards the lumen. It may or may not be associated with dysplasia. It is
typically created as the result of alteration of proliferative zone of the crypts also leading to
“hypermaturation” / accumulation of apoptotic cells / shedding of the aging cell. Serration leads
to various morphologic patterns creating three main categories of lesions; hyperplastic polyp,
sessile serrated adenoma and traditional serrated adenoma.

Hyperplastic polyps (HP) are serrated lesions with symmetrical normally placed proliferative
zone leading to simple tubular crypts with serrated epithelium. The micro-vesicular subtype
(MVHP) shows prominent serration with many cells containing numerous tiny mucin vacuoles;
the epithelium of the mucinous type/ Goblet Cell rich type (GCHP) is filled with large goblet
cells. The latter is exclusively left sides and seems not to have significant propensity for
progression to cancer and typically show Kras mutation rather than BRAF that is characteristic
of MVHP.

It has been suggested that MVHP can progress to SSA or dysplastic lesions. There is also
suggestive evidence that MVHP may progress to cancer skipping SSA stage.

128

Sessile Serrated Adenomas (SSA) are serrated lesions with asymmetrically placed proliferative
zone to the side of the crypt leading to complex, inverted, branched (inverted L or T) and dilated
crypts yet maintaining orientation towards muscularis mucosa.

With progression to microsatellite instable (MSI) carcinomas, dysplasia develops and can
be observed in combination with dysplastic-SSA adenomas.

Traditional Serrated Adenoma (TSA) are serrated lesions with multifocal asymmetrically placed
proliferative zones along the side of the crypts leading to complex large crypts surrounded by
numerous tiny ectopic crypt lumens along the sides as well as profuse micropapillary infolding
towards the lumen.

The orientation towards the muscularis mucosa is lost similar to tubular adenomas.
Conventional APC-mutated adenomas with a serrated growth pattern vs. serration in TSA is
evident when comparing a TSA with a dysplastic adenoma.

Dysplastic (traditional) adenomas contain phenotypically altered cells that are typically, but not
exclusively, found in advanced tumors that are part of the MSS-APC tumor suppressor pathway
(TA, TVA, VA), but are also observed in CIMP, not APC-associated and MSI pathway (SSA) as
well as less clearly understood dysplasia associated with TSA. Morphologically dysplastic crypts
are lined by dysplastic cells that show elongated hyperchromatic nuclei with high N/C ratio and
often little mucin.
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Dysplasia can by classified into low-grade and high grade. High-grade dysplasia is
architecturally characterized by complex gland architecture, with gland-in-gland formation,
cross-bridging of epithelium and often shows epithelial cell stratification. Cytologically, cells
possess hyper-chromatic nuclei and marked increased N/C ratio leading to marked crowding
appearance. The orientation of nuclei towards the basement membrane is typically lost.
Occasionally, the cytologic anaplasia is so severe that in the absence of architectural complexity
described above the diagnosis of high-grade dysplasia is justified. Anything less severe than the
above description is categorized as low-grade dysplasia. It should be emphasized that a typical
TA / TVA / VA would have smooth non-serrated epithelial borders. However, occasionally
serration may be present in these lesions, and this would not change the classification or
diagnostic implications.
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